<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87894</article-id><article-id pub-id-type="doi">10.7554/eLife.87894</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87894.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Identifying metabolic features of colorectal cancer liability using Mendelian randomization</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-221877"><name><surname>Bull</surname><given-names>Caroline</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2176-5120</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-290928"><name><surname>Hazelwood</surname><given-names>Emma</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4888-6037</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-248289"><name><surname>Bell</surname><given-names>Joshua A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104528"><name><surname>Tan</surname><given-names>Vanessa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7938-127X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311833"><name><surname>Constantinescu</surname><given-names>Andrei-Emil</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195893"><name><surname>Borges</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222211"><name><surname>Legge</surname><given-names>Danny</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3897-5861</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-261586"><name><surname>Burrows</surname><given-names>Kimberley</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311834"><name><surname>Huyghe</surname><given-names>Jeroen R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6027-9806</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311835"><name><surname>Brenner</surname><given-names>Hermann</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150916"><name><surname>Castellvi-Bel</surname><given-names>Sergi</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311836"><name><surname>Chan</surname><given-names>Andrew T</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310185"><name><surname>Kweon</surname><given-names>Sun-Seog</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294653"><name><surname>Le Marchand</surname><given-names>Loic</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311837"><name><surname>Li</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-261588"><name><surname>Cheng</surname><given-names>Iona</given-names></name><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311838"><name><surname>Pai</surname><given-names>Rish K</given-names></name><xref ref-type="aff" rid="aff21">21</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310189"><name><surname>Figueiredo</surname><given-names>Jane C</given-names></name><xref ref-type="aff" rid="aff22">22</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310191"><name><surname>Murphy</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311839"><name><surname>Gunter</surname><given-names>Marc J</given-names></name><xref ref-type="aff" rid="aff24">24</xref><xref ref-type="aff" rid="aff25">25</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38006"><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-248290"><name><surname>Vincent</surname><given-names>Emma E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8917-7384</contrib-id><email>emma.vincent@bristol.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>MRC Integrative Epidemiology Unit at the University of Bristol</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>Population Health Sciences, Bristol Medical School, University of Bristol</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>Translational Health Sciences, Bristol Medical School, University of Bristol</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Public Health Sciences Division, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cdgtt98</institution-id><institution>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ)</institution></institution-wrap><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01txwsw02</institution-id><institution>Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)</institution></institution-wrap><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cdgtt98</institution-id><institution>German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)</institution></institution-wrap><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021018s57</institution-id><institution>Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Broad Institute of Harvard and MIT</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kzjxq56</institution-id><institution>Department of Preventive Medicine, Chonnam National University Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Gwangju</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/054gh2b75</institution-id><institution>Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Hwasun</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00kt3nk56</institution-id><institution>University of Hawaii Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Honolulu</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0153tk833</institution-id><institution>Department of Family Medicine, University of Virginia</institution></institution-wrap><addr-line><named-content content-type="city">Charlottesville</named-content></addr-line><country>United States</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Epidemiology and Biostatistics, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03jp40720</institution-id><institution>Department of Pathology and Laboratory Medicine, Mayo Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Scottsdale</named-content></addr-line><country>United States</country></aff><aff id="aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pammg90</institution-id><institution>Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03zb6nw87</institution-id><institution>Nutrition and Metabolism Branch, International Agency for Research on Cancer</institution></institution-wrap><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff><aff id="aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03zb6nw87</institution-id><institution>Nutrition and Metabolism Branch, International Agency for Research on Cancer</institution></institution-wrap><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff><aff id="aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hägg</surname><given-names>Sara</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Karolinska Institutet</institution></institution-wrap><country>Sweden</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>12</month><year>2023</year></pub-date><volume>12</volume><elocation-id>RP87894</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-03-23"><day>23</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-03-10"><day>10</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.03.10.23287084"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-07-25"><day>25</day><month>07</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87894.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-10-17"><day>17</day><month>10</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87894.2"/></event></pub-history><permissions><copyright-statement>© 2023, Bull, Hazelwood et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Bull, Hazelwood et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87894-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-87894-figures-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival.</p></sec><sec id="abs2"><title>Methods:</title><p>To investigate whether changes in circulating metabolites characterize the early stages of colorectal cancer (CRC) development, we examined the associations between a genetic risk score (GRS) associated with CRC liability (72 single-nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N = 6221). Linear regression models were applied to examine the associations between genetic liability to CRC and circulating metabolites measured in the same individuals at age 8 y, 16 y, 18 y, and 25 y.</p></sec><sec id="abs3"><title>Results:</title><p>The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P &lt; 0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N = 118,466, median age 58 y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk.</p></sec><sec id="abs4"><title>Conclusions:</title><p>These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism and suggest that fatty acids may play an important role in CRC development.</p></sec><sec id="abs5"><title>Funding:</title><p>This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - <ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/acrc/">http://www.bristol.ac.uk/acrc/</ext-link>.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Colorectal cancer, or bowel cancer, is the fourth most common cause of death from cancer worldwide. Understanding how the cancer develops and recognizing early signs is essential, as people who receive treatment early on have higher survival rates.</p><p>One way to boost early detection and disease survival rates is through identifying early colorectal cancer biomarkers. For example, metabolites produced when cells process nutrients have been shown to play a role in the development of colon cancer. Certain metabolites could therefore serve as biomarkers, which can be detected in routine blood tests. But first, scientists need to identify the exact metabolic processes involved in cancer development.</p><p>Bull, Hazelwood et al. show that fat metabolites during early adulthood may help predict colorectal cancer risk. In the experiments, the team assessed the link between an individual’s genetic risk for developing colorectal cancer and metabolites in their blood. By looking at data from over 6,000 individuals living in the UK, followed from early life into adulthood, they found higher fatty acid and low-density lipoprotein levels in young adults at risk of colorectal cancer. However, the results could not be replicated in a separate cohort study of middle-aged adults. Bull, Hazelwood et al. noted that many individuals in this older age group use fat-targeting drugs called statins, which may have obscured this connection.</p><p>The study of Bull, Hazelwood et al. shows that colorectal cancer risk indicators may be present from adolescence to around 40 years, before most individuals are diagnosed. The results suggest this may be a window for early detection and preventive interventions. It also highlights that differences in fat metabolism, possibly linked to genetic differences, may underlie colorectal cancer risk. More studies are needed to better understand how and whether interventions targeting fat levels may help prevent colorectal cancer development.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Mendelian randomization</kwd><kwd>obesity</kwd><kwd>colorectal cancer</kwd><kwd>metabolomics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.35802/204813</award-id><principal-award-recipient><name><surname>Bell</surname><given-names>Joshua A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC_UU_00011/4</award-id><principal-award-recipient><name><surname>Bull</surname><given-names>Caroline</given-names></name><name><surname>Hazelwood</surname><given-names>Emma</given-names></name><name><surname>Bell</surname><given-names>Joshua A</given-names></name><name><surname>Tan</surname><given-names>Vanessa</given-names></name><name><surname>Constantinescu</surname><given-names>Andrei-Emil</given-names></name><name><surname>Borges</surname><given-names>Carolina</given-names></name><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name><name><surname>Vincent</surname><given-names>Emma E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000361</institution-id><institution>Diabetes UK</institution></institution-wrap></funding-source><award-id>17/0005587</award-id><principal-award-recipient><name><surname>Bull</surname><given-names>Caroline</given-names></name><name><surname>Legge</surname><given-names>Danny</given-names></name><name><surname>Vincent</surname><given-names>Emma E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.35802/202802</award-id><principal-award-recipient><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>102215/2/13/2</award-id><principal-award-recipient><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>102215/2/13/2</award-id><principal-award-recipient><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C18281/A19169</award-id><principal-award-recipient><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C18281/A30905</award-id><principal-award-recipient><name><surname>Hazelwood</surname><given-names>Emma</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C18281/A29019</award-id><principal-award-recipient><name><surname>Hazelwood</surname><given-names>Emma</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/N0137941/1</award-id><principal-award-recipient><name><surname>Constantinescu</surname><given-names>Andrei-Emil</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/P014054/1</award-id><principal-award-recipient><name><surname>Borges</surname><given-names>Carolina</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Increased genetic liability to colorectal cancer is associated with altered levels of circulating metabolites, including fatty acids, up to 40 years before average age of diagnosis.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Colorectal cancer (CRC) is the third most frequently diagnosed cancer worldwide and the fourth most common cause of death from cancer (<xref ref-type="bibr" rid="bib25">Ferlay et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Clinton et al., 2018</xref>). There is a genetic component to risk of the disease, which is thought to explain up to 35% of variability in CRC risk (<xref ref-type="bibr" rid="bib39">Huyghe et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Czene et al., 2002</xref>; <xref ref-type="bibr" rid="bib47">Lichtenstein et al., 2000</xref>). In addition, modifiable lifestyle factors, including obesity, consumption of processed meat, and alcohol, are thought to increase CRC risk (<xref ref-type="bibr" rid="bib18">Clinton et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Händel et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">McNabb et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Lauby-Secretan et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Gui et al., 2023</xref>). However, the underlying biological pathways remain unclear, which limits targeted prevention strategies. While CRC has higher mortality rates when diagnosed at later stages, early-stage CRC or precancerous lesions are largely treatable, meaning CRC screening programmes have the potential to be highly effective (<xref ref-type="bibr" rid="bib57">Meester et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Cardoso et al., 2021</xref>). Due to the lack of known predictive biomarkers for CRC, wide-scale screening (if implemented at all) is expensive and often targeted crudely by age range. Identifying biomarkers predictive of CRC, or with causal roles in disease development, is therefore vital.</p><p>One potential source of biomarkers for CRC risk is the circulating metabolome, which offers a dynamic insight into cellular processes and disease states. It is increasingly clear from mechanistic studies that both systemic and intracellular tumour metabolism play an important role in CRC development and progression (<xref ref-type="bibr" rid="bib63">Qiu et al., 2009</xref>; <xref ref-type="bibr" rid="bib77">Ward and Thompson, 2012</xref>). Interestingly, several major risk factors for CRC are known to have profound effects on metabolism (<xref ref-type="bibr" rid="bib65">Rattray et al., 2017</xref>). For instance, obesity has been shown via conventional observational and Mendelian randomization (MR) analyses to strongly alter circulating metabolite levels (<xref ref-type="bibr" rid="bib30">Gui et al., 2023</xref>; <xref ref-type="bibr" rid="bib70">Singla et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Papandreou et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Ahmad et al., 2022</xref>). This suggests that the circulating metabolome may play a mediating role in the relationship between at least some common risk factors, such as obesity, and CRC – or at least might be a useful biomarker for disease or intermediates thereof. In particular, previous work has highlighted polyunsaturated fatty acids (PUFAs) as potentially having a role in CRC development. The term PUFA includes omega-3 and -6 fatty acids. Recent MR work has highlighted a possible link between PUFAs, in particular omega-6 PUFAs, and CRC risk (<xref ref-type="bibr" rid="bib35">Haycock et al., 2023</xref>). Further investigating the relationship between CRC and circulating metabolites may therefore provide powerful insights into the causal pathways underlying disease risk or alternatively may be valuable in prediction and early diagnosis.</p><p>MR is a genetic epidemiological approach used to evaluate causal relationships between traits (<xref ref-type="bibr" rid="bib81">Yarmolinsky et al., 2018</xref>; <xref ref-type="bibr" rid="bib71">Smith and Ebrahim, 2003</xref>). This method uses genetic variation as a proxy measure for traits in an instrumental variable framework to assess the causal relevance of the traits in disease development. As germline genetic variants are theoretically randomized between generations and fixed at conception, this approach should be less prone to bias and confounding than conventional analyses undertaken in an observational context. Conventionally, MR is used to investigate the effect of an exposure on a disease outcome. In reverse MR, genetic instruments proxy the association between liability to a disease and other traits (<xref ref-type="bibr" rid="bib38">Holmes and Davey Smith, 2019</xref>). This approach can identify the biomarkers which cause the disease, are predictive for the disease, or have diagnostic potential (<xref ref-type="bibr" rid="bib38">Holmes and Davey Smith, 2019</xref>). Given the suspected importance of the circulating metabolome in CRC development, employing both reverse MR and conventional forward MR for metabolites in the same study may be an efficient approach for revealing causal and predictive biomarkers for CRC. Although previous observational studies have investigated associations between the circulating metabolome and CRC risk, these studies may have been influenced by confounding bias, which should be less relevant to MR analyses (<xref ref-type="bibr" rid="bib28">Gao et al., 2023</xref>; <xref ref-type="bibr" rid="bib64">Rattner et al., 2022</xref>; <xref ref-type="bibr" rid="bib46">Leichtle et al., 2012</xref>; <xref ref-type="bibr" rid="bib67">Ritchie et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Nishiumi et al., 2012</xref>; <xref ref-type="bibr" rid="bib51">Ma et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Bertini et al., 2012</xref>; <xref ref-type="bibr" rid="bib83">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Farshidfar et al., 2016</xref>; <xref ref-type="bibr" rid="bib23">Farshidfar et al., 2012</xref>). Additionally, these studies focussed on adults, who commonly take medications which may confound metabolite associations, further complicating interpretations.</p><p>Here, we applied a reverse MR framework to identify circulating metabolites which are associated with CRC liability across different stages of the early life course (spanning childhood to young adulthood, when use of medications and CRC are both rare) using data from a birth cohort study. We then attempted to replicate these results using reverse two-sample MR in an independent cohort of middle-aged adults (UK Biobank). We then performed conventional ‘forward’ MR of metabolites onto CRC risk using large-scale cancer consortia data to identify the metabolites which may have a causal role in CRC development.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study populations</title><p>This study uses data from two cohort studies: the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (generation 1) cohort (individual-level data) and the UK Biobank cohort (summary-level data); plus summary-level data from a genome-wide association study (GWAS) meta-analysis of CRC comprising the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Colorectal Transdisciplinary Study (CORECT), and Colon Cancer Family Registry (CCFR).</p><p>ALSPAC is a population-based birth cohort study in which 14,541 pregnant women with an expected delivery date between 1 April 1991 and 31 December 1992 were recruited from the former Avon County of southwest England (<xref ref-type="bibr" rid="bib8">Boyd et al., 2013</xref>). Since then, 13,988 offspring alive at 1 y have been followed repeatedly with questionnaire- and clinic-based assessments (<xref ref-type="bibr" rid="bib27">Fraser et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Northstone et al., 2019</xref>). Sufficient information was available on 6221 of these individuals to be included in our analysis, as metabolomics was not performed for all individuals in the ALSPAC study. Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at the University of Bristol (<xref ref-type="bibr" rid="bib33">Harris et al., 2009</xref>) REDCap is a secure, web-based software platform designed to support data capture for research studies. Offspring genotype was assessed using the Illumina HumanHap550 quad chip platform. Quality control measures included exclusion of participants with sex mismatch, minimal or excessive heterozygosity, disproportionately missing data, insufficient sample replication, cryptic relatedness, and non-European ancestry. Imputation was performed using the Haplotype Reference Consortium (HRC) panel. Offspring were considered for the current analyses if they had no older siblings in ALSPAC (203 excluded) and were of white ethnicity (based on reports by parents, 604 excluded) to reduce the potential for confounding by genotype. The study website contains details of all available data through a fully searchable data dictionary and variable search tool (<ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/researchers/our-data/">http://www.bristol.ac.uk/alspac/researchers/our-data/</ext-link>).</p><p>UK Biobank is a population-based cohort study based in 22 centres across the UK (<xref ref-type="bibr" rid="bib72">Sudlow et al., 2015</xref>). The cohort is made up of around 500,000 adults aged 40–80 years old, who were enrolled between 2006 and 2010. Genotyping data is available for 488,377 participants (<xref ref-type="bibr" rid="bib12">Bycroft et al., 2018</xref>). Participants were genotyped using one of two arrays – either the Applied Biosystems UK BiLEVE Axiom Array by Affymetrix (now part of Thermo Fisher Scientific) or the closely related Applied Biosystems UK Biobank Axiom Array. Approaches based on principal component analysis (PCA) were used to account for population structure. Individuals were excluded if reported sex differed from inferred sex based on genotyping data; if they had sex chromosome karyotypes which were not XX or XY; if they were outliers in terms of heterozygosity and missing rates; or if they had high relatedness to another participant. Multiallelic SNPs or those with a minor allele frequency of below 1% were removed. Imputation was performed using the UK10K haplotype and HRC reference panels.</p><p>The GWAS meta-analysis for CRC included up to 52,775 cases and 45,940 controls (<xref ref-type="bibr" rid="bib39">Huyghe et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">Huyghe et al., 2021</xref>). This sample excluded cases and controls from UK Biobank to avoid potential bias due to sample overlap which may be problematic in MR analyses (<xref ref-type="bibr" rid="bib10">Burgess et al., 2016</xref>). Cases were diagnosed by a physician and recorded overall and by site (colon, 28,736 cases; proximal colon, 14,416 cases; distal colon, 12,879 cases; and rectal, 14,150 cases). Colon cancer included proximal colon (any primary tumour arising in the caecum, ascending colon, hepatic flexure, or transverse colon), distal colon (any primary tumour arising in the pleenic flexure, descending colon, or sigmoid colon), and colon cases with unspecified site. Rectal cancer included any primary tumour arising in the rectum or rectosigmoid junction (<xref ref-type="bibr" rid="bib39">Huyghe et al., 2019</xref>). Approximately 92% of participants in the overall CRC GWAS were white European (~8% were East Asian). All participants included in site-specific CRC analyses were of European ancestry. Imputation was performed using the Michigan imputation server and HRC r1.0 reference panel. Regression models were further adjusted for age, sex, genotyping platform, and genomic principal components as described previously (<xref ref-type="bibr" rid="bib39">Huyghe et al., 2019</xref>).</p></sec><sec id="s2-2"><title>Assessment of CRC genetic liability</title><p>Genetic liability to CRC was based on single-nucleotide polymorphisms (SNPs) associated with CRC case status at genome-wide significance (p&lt;5 × 10<sup>−8</sup>). A total of 108 independent SNPs reported by two major GWAS meta-analyses were eligible for inclusion in a CRC genetic risk score (GRS) (<xref ref-type="bibr" rid="bib39">Huyghe et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Law et al., 2019</xref>). The set of SNPs was filtered, excluding 36 SNPs that were in linkage disequilibrium based on R<sup>2</sup> &gt; 0.001 using the TwoSampleMR package (SNPs with the lowest p-values were retained) (<xref ref-type="bibr" rid="bib37">Hemani et al., 2018</xref>). This left 72 SNPs independently associated with CRC (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>), 65 of which were available in imputed ALSPAC genotype data post quality control. As GWAS of site-specific CRC have identified marked heterogeneity (<xref ref-type="bibr" rid="bib40">Huyghe et al., 2021</xref>), GRS describing site-specific CRCs were constructed for sensitivity analyses using the same process outlined above. The GRS for colon cancer, rectal cancer, proximal colon cancer, and distal colon cancer were comprised of 38, 25, 20, and 24 variants, respectively (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). For overall CRC and site-specific CRC analyses, sensitivity analyses excluding any SNPs in the FADS cluster (i.e. within the gene regions of <italic>FADS1</italic>, <italic>FADS2</italic>, or <italic>FADS3</italic>) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>) were performed given a likely role for these SNPs in influencing circulating metabolite levels directly, in particular via lipid metabolism (i.e. not primarily due to CRC) (<xref ref-type="bibr" rid="bib49">Lu et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Zaytseva et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">ClinicalTrials.gov, 2022</xref>; <xref ref-type="bibr" rid="bib26">Fhu and Ali, 2020</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Kathiresan et al., 2009</xref>; <xref ref-type="bibr" rid="bib73">Tanaka et al., 2009</xref>).</p></sec><sec id="s2-3"><title>Assessment of circulating metabolites</title><p>Circulating metabolite measures were drawn from ALSPAC and UK Biobank using the same targeted metabolomics platform. In ALSPAC, participants provided non-fasting blood samples during a clinic visit while aged approximately 8 y, and fasting blood samples from clinic visits while aged approximately 16 y, 18 y, and 25 y. Proton nuclear magnetic resonance (<sup>1</sup>H-NMR) spectroscopy was performed on ethylenediaminetetraacetic acid (EDTA) plasma (stored at or below –70°C pre-processing) to quantify a maximum of 231 metabolites (<xref ref-type="bibr" rid="bib78">Würtz et al., 2017</xref>). Quantified metabolites included the cholesterol and triglyceride content of lipoprotein particles; the concentrations and diameter/size of these particles; apolipoprotein B and apolipoprotein A-1 concentrations; as well as fatty acids and their ratios to total fatty acid concentration, branched chain and aromatic amino acids, glucose and pre-glycaemic factors including lactate and citrate, fluid balance factors including albumin and creatinine, and the inflammatory marker glycoprotein acetyls (GlycA). This metabolomics platform has limited coverage of fatty acids. In UK Biobank, EDTA plasma samples from 117,121 participants, a random subset of the original ∼500,000 who provided samples at assessment centres between 2006 and 2013, were analysed between 2019 and 2020 for levels of 249 metabolic traits (168 concentrations plus 81 ratios) using the same high-throughput <sup>1</sup>H-NMR platform. Data pre-processing and QC steps are described previously (<xref ref-type="bibr" rid="bib78">Würtz et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Julkunen et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Bycroft et al., 2018</xref>). To allow comparability between MR and GRS estimates, all metabolite measures were standardized and normalized using rank-based inverse normal transformation. For descriptive purposes in ALSPAC, body mass index (BMI) was calculated at each time point as weight (kg) divided by squared height (m<sup>2</sup>) based on clinic measures of weight to the nearest 0.1 kg using a Tanita scale and height measured in light clothing without shoes to the nearest 0.1 cm using a Harpenden stadiometer.</p><p>CRC liability variants were combined into a GRS using PLINK 1.9, specifying the effect (risk raising) allele and coefficient (logOR) with estimates from the CRC GWAS used as external weights (<xref ref-type="bibr" rid="bib39">Huyghe et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Law et al., 2019</xref>). GRSs were calculated as the number of effect alleles (or dosages if imputed) at each SNP (0, 1, or 2) multiplied by its weighting, summing these, and dividing by the total number of SNPs used. Z-scores of GRS variables were calculated to standardize scoring.</p></sec><sec id="s2-4"><title>Statistical approach</title><p>An overview of the study design is presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>. To estimate the effect of increased genetic liability to CRC on circulating metabolites, we conducted a GRS analysis in ALSPAC and reverse two-sample MR analyses in UK Biobank. Estimates were interpreted within a ‘reverse MR’ framework (<xref ref-type="bibr" rid="bib38">Holmes and Davey Smith, 2019</xref>), wherein results are taken to reflect ‘metabolic features’ of CRC liability which could capture causal or predictive metabolite–disease associations. To clarify the direction of metabolite–CRC associations, we additionally performed conventional ‘forward’ two-sample MR analyses to estimate the effect of circulating metabolites on CRC risk using large-scale GWAS data on metabolites and CRC.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Study design.</title><p>First, linear regression models were used to examine the relationship between genetic susceptibility to adult colorectal cancer (CRC) and circulating metabolites measured in the Avon Longitudinal Study of Parents and Children (ALSPAC) participants at age 8 y, 16 y, 18 y, and 25 y. Next, we performed a reverse Mendelian randomization analysis to identify metabolites influenced by CRC susceptibility in an independent population of adults. Finally, we performed a conventional (forward) Mendelian randomization analysis of circulating metabolites on CRC to identify metabolites causally associated with CRC risk. Consistent evidence across all three methodological approaches was interpreted to indicate a causal role for a given metabolite in CRC aetiology.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig1-v1.tif"/></fig><sec id="s2-4-1"><title>Associations of CRC liability with circulating metabolites in early life</title><p>Separate linear regression models with robust standard errors were used to estimate coefficients and 95% confidence intervals (95% CIs) for associations of GRSs with each metabolite as a dependent variable measured on the same individuals at age 8 y, 16 y, 18 y, and 25 y, adjusted for sex and age at the time of metabolite assessment. To aid interpretations, estimates were multiplied by 0.693 (log<sub>e</sub>2) to reflect SD-unit differences in metabolites per doubling of genetic liability to CRC (<xref ref-type="bibr" rid="bib11">Burgess and Labrecque, 2018</xref>). The Benjamini–Hochberg method was used to adjust p-values for multiple testing and an adjusted p-value of &lt;0.05 was used as a heuristic for evidence for association given current sample sizes (<xref ref-type="bibr" rid="bib3">Benjamini and Hochberg, 1995</xref>).</p></sec><sec id="s2-4-2"><title>Reverse MR of the effects of CRC liability on circulating metabolites in middle adulthood</title><p>‘Reverse’ MR analyses (<xref ref-type="bibr" rid="bib38">Holmes and Davey Smith, 2019</xref>) were conducted using UK Biobank for outcome datasets in two-sample MR to examine the effect of CRC liability on circulating metabolites. SNP-outcome (metabolite) estimates were obtained from a GWAS of metabolites in UK Biobank (<xref ref-type="bibr" rid="bib16">Clayton et al., 2022</xref>; <xref ref-type="bibr" rid="bib5">Borges et al., 2022a</xref>). Prior to GWAS, all metabolite measures were standardized and normalized using rank-based inverse normal transformation. Genetic association data for metabolites were retrieved using the MRC IEU UK Biobank GWAS pipeline (<xref ref-type="bibr" rid="bib21">Data.bris, 2022</xref>). Full summary statistics are available via the IEU Open GWAS project (<xref ref-type="bibr" rid="bib38">Holmes and Davey Smith, 2019</xref>; <xref ref-type="bibr" rid="bib22">Elsworth et al., 2020</xref>). Up to three statistical methods were used to generate reverse MR estimates of the effect of CRC liability on circulating metabolites using the TwoSampleMR package (<xref ref-type="bibr" rid="bib36">Hemani et al., 2016</xref>): random-effects inverse variance weighted (IVW), weighted-median, and weighted-mode, which each make differing assumptions about directional pleiotropy and SNP heterogeneity (<xref ref-type="bibr" rid="bib7">Bowden et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Hartwig et al., 2017</xref>). The IVW MR model will produce biased effect estimates in the presence of horizontal pleiotropy, that is, where one or more genetic variant(s) included in the instrument affect the outcome by a pathway other than through the exposure. In the weighted median model, each genetic variant is weighted according to its distance from the median effect of all genetic variants. Thus, the weighted median model will provide an unbiased estimate when at least 50% of the information in an instrument comes from genetic variants that are not horizontally pleiotropic. The weighted mode model uses a similar approach but weights genetic instruments according to the mean effect. In this model, over 50% of the weight of the genetic instrument can be contributed to by genetic variants which are horizontally pleiotropic, but the most common amount of pleiotropy must be zero (known as the Zero Modal Pleiotropy Assumption [ZEMPA]) (<xref ref-type="bibr" rid="bib34">Hartwig et al., 2017</xref>). As above, estimates were multiplied by 0.693 (log<sub>e</sub>2) to reflect SD-unit differences in metabolites per doubling of genetic liability to CRC (<xref ref-type="bibr" rid="bib11">Burgess and Labrecque, 2018</xref>).</p></sec><sec id="s2-4-3"><title>Forward MR of the effects of metabolites on CRC</title><p>Forward MR analyses were conducted using summary statistics from UK Biobank for the same NMR-measured metabolites (SNP-exposure) and from GECCO/CORECT/CCFR as outlined above (SNP-outcome). We identified SNPs that were independently associated (R<sup>2</sup> &lt; 0.001 and p&lt;5 × 10<sup>–8</sup>) with metabolites from a GWAS of 249 metabolites in UK Biobank described above. As before, we used up to three statistical methods to generate MR estimates of the effect of circulating metabolites on CRC risk (overall and site-specific): random-effects IVW, weighted median, and weighted mode. The Benjamini–Hochberg method was used to adjust p-values for multiple testing and an adjusted p-value of &lt;0.05 was used as a heuristic for nominal evidence for a causal effect (<xref ref-type="bibr" rid="bib3">Benjamini and Hochberg, 1995</xref>). MR outputs are beta coefficients representing the logOR for CRC per SD higher metabolite, exponentiated to reflect the OR for CRC per SD metabolite.</p><p>MR analyses were performed in R version 4.0.3 (<xref ref-type="bibr" rid="bib66">R Development Core Team, 2021</xref>) and GRS analyses in Stata 16.1 (StataCorp, College Station, TX). The ggforestplot R package was used to generate results visualizations (<xref ref-type="bibr" rid="bib69">Scheinin et al., 2022</xref>).</p></sec></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Associations of CRC liability with circulating metabolites in early life</title><p>At the time the ALSPAC blood samples were taken, the mean age of participants was 7.5 y (N = 4767), 15.5 y (N = 2930), 17.8 y (N = 2613), and 24.5 y (N = 2559) for the childhood, early adolescence, late adolescence, and young adulthood time points, respectively. The proportion of participants which were male were 50.5, 47.4, 44.5, and 39.1% and mean BMI was 16.2, 21.4, 22.7, and 24.8 kg/m<sup>2</sup> for each time point, respectively. The socio-demographic profile of ALSPAC offspring participants has been reported previously (<xref ref-type="bibr" rid="bib8">Boyd et al., 2013</xref>). The mean and standard deviation (SD) values for metabolites on each measurement occasion in ALSPAC are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>.</p><p>In the GRS analysis, there was no strong evidence of association of CRC liability with metabolites at age 8 y (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). At age 16 y, there was evidence for association with several lipid traits including higher cholesteryl esters to total lipids ratio in large low-density lipoprotein (LDL) (SD change per doubling CRC liability = 0.06, 95% CI = 0.02–0.10) and higher cholesterol in very small very low-density lipoprotein (VLDL) (SD change per doubling CRC liability = 0.06, 95% CI = 0.03–0.10). There was strong evidence for association with several traits at age 18 y including higher non-high-density lipoprotein (non-HDL) lipids, for example, a 1 doubling CRC liability was associated with higher levels of total cholesterol (SD change = 0.05 95% CI = 0.01–0.09), VLDL-cholesterol (SD change = 0.05, 95% CI = 0.01–0.09), LDL-cholesterol (SD change = 0.06, 95% CI = 0.02–0.09), apolipoproteins (apolipoprotein B [SD change = 0.06, 95% CI = 0.02–0.09]), and fatty acids (omega-3 [SD change = 0.08, 95% CI = 0.04–0.11], docosahexaenoic acid [DHA] [SD change = 0.05, 95% CI = 0.02–0.09]) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). <xref ref-type="fig" rid="fig2">Figure 2</xref> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s6">6</xref>) shows results for all clinically validated metabolites. At age 25 y, there was no strong evidence of association of CRC liability with metabolites. In anatomical site-specific analyses, there was strong evidence for association of liability to colon cancer with omega-3 (SD change = 0.07, 95% CI = 0.03–0.11) and DHA (SD change = 0.07, 95% CI = 0.03–0.10) at age 18 y. There was little evidence for any associations at any other CRC site or age (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). When SNPs in the FADS cluster gene regions were excluded due to possible horizontal pleiotropy given the role of FADS in lipid metabolism, there was a reduction in strength of evidence for an association of liability to CRC with any metabolite measured, although estimates were in a largely consistent direction with the prior analysis (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Associations of genetic liability to adult colorectal cancer (based on a 72 single-nucleotide polymorphism [SNP] genetic risk score) with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y [N = 4767], 16 y [N = 2930], 18 y [N = 2613], and 25 y [N = 2559]).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to colorectal cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Associations of genetic liability to adult colon cancer with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y, 16 y, 18 y, and 25 y).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to colon cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Associations of genetic liability to proximal colon cancer with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y, 16 y, 18 y, and 25 y).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to proximal colon cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Associations of genetic liability to distal colon cancer with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y, 16 y, 18 y, and 25 y).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to distal colon cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Associations of genetic liability to rectal cancer with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y, 16 y, 18 y, and 25 y).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to rectal cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Associations of genetic liability to adult colorectal cancer (excluding rs174533) with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y, 16 y, 18 y, and 25 y).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to colorectal cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-figsupp5-v1.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title>Associations of genetic liability to adult colon cancer (excluding rs174535) with clinically validated metabolic traits at different early life stages among the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (age 8 y, 16 y, 18 y, and 25 y).</title><p>Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to colorectal cancer (purple, 8 y; turquoise, 16 y; red, 18 y; black, 25 y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig2-figsupp6-v1.tif"/></fig></fig-group></sec><sec id="s3-2"><title>Reverse MR of the effects of CRC liability on circulating metabolites in middle adulthood</title><p>All instrument sets from the reverse MR analysis had an F-statistic greater than 10 (minimum F-statistic = 36, median = 40), suggesting that our analyses did not suffer from weak instrument bias (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). There was little evidence of an association of CRC liability (overall or by anatomical site) on any of the circulating metabolites investigated, including when the SNP in the <italic>FADS</italic> gene region was excluded, based on our pre-determined cut-off of FDR-P &lt; 0.05; however, the direction of effect estimates was largely consistent with those seen in ALSPAC GRS analyses, with higher CRC liability weakly associated with higher non-HDLs, lipoproteins, and fatty acid levels (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f and g</xref>). <xref ref-type="fig" rid="fig3">Figure 3</xref> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s3">3</xref>) shows the results for clinically validated metabolites. In subsite stratified analyses, there was strong evidence for a causal effect of genetic liability to proximal colon cancer on several traits, including total fatty acids (SD change per doubling of liability = 0.02, 95% CI = 0.01–0.04) and omega-6 fatty acids (SD change per doubling of liability = 0.03, 95% CI = 0.01–0.05).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Associations of genetic liability to colorectal cancer with clinically validated metabolic traits in an independent sample of adults (UK Biobank, N = 118,466, median age 58 y) based on reverse two-sample Mendelian randomization analyses.</title><p>Estimates shown are beta coefficients representing the SD-unit difference in metabolic trait per doubling of liability to colorectal cancer. Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Associations of genetic liability to colorectal cancer with clinically validated metabolic traits in an independent sample of adults based on reverse two-sample Mendelian randomization analyses.</title><p>Estimates shown are beta coefficients representing the SD-unit difference in metabolic trait per doubling of liability to colorectal cancer by site (colorectal, colon, distal colon, proximal colon, and rectal cancer). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Associations of genetic liability to colorectal cancer (excluding genetic variants in the FADS gene region) with clinically validated metabolic traits in an independent sample of adults based on reverse two-sample Mendelian randomization analyses.</title><p>Estimates shown are beta coefficients representing the SD-unit difference in metabolic trait per doubling of liability to colorectal cancer. Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Associations of genetic liability to colorectal and colon cancer with clinically validated metabolic traits in an independent sample of adults based on reverse two-sample Mendelian randomization analyses with FADS variants excluded from colorectal cancer instruments.</title><p>Estimates shown are beta coefficients representing the SD-unit difference in metabolic trait per doubling of liability to colorectal cancer by site (colorectal, colon). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig3-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s3-3"><title>Forward MR for the effects of metabolites on CRC risk</title><p>All instrument sets from the forward MR analysis had an F-statistic greater than 10 (minimum F-statistic = 54, median = 141), suggesting that our analyses were unlikely to suffer from weak instrument bias (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h and i</xref>). There was strong evidence for an effect of several fatty acid traits on overall CRC risk, including of omega-3 fatty acids (CRC OR = 1.13, 95% CI = 1.06–1.21), DHA (OR CRC = 1.76, 95% CI = 1.08–1.28), ratio of omega-3 fatty acids to total fatty acids (OR CRC = 1.18, 95% CI = 1.11–1.25), ratio of DHA to total fatty acids (CRC OR = 1.20, 95% CI = 1.10–1.31), and ratio of omega-6 fatty acids to omega-3 fatty acids (CRC OR = 0.86, 95% CI = 0.80–9.13) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1j</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s3">3</xref>). These estimates were overlapping with variable precision in MR sensitivity models. When SNPs in the <italic>FADS</italic> gene region were excluded, there was little evidence for a causal effect of any metabolite investigated on CRC risk based on the predetermined FDR-P cut-of off &lt;0.05, although the directions of effect estimates were consistent with previous analyses (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1k</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Associations of clinically validated metabolites with colorectal cancer based on conventional (forward) two-sample Mendelian randomization analyses in individuals from UK Biobank (N = 118,466, median age 58 y).</title><p>Estimates shown are beta coefficients representing the logOR for colorectal cancer per SD metabolite. Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Associations of clinically validated metabolites with colorectal cancer by site (colorectal, colon, distal colon, proximal colon, and rectal cancer) based on conventional (forward) two-sample Mendelian randomization analyses.</title><p>Estimates shown are ORs for colorectal cancer per SD metabolite. Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Associations of clinically validated metabolites with colorectal cancer based on conventional (forward) two sample Mendelian randomization analyses with FADS variants excluded from metabolite instruments.</title><p>Estimates shown are ORs for colorectal cancer per SD metabolite. Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Associations of clinically validated metabolites with colorectal cancer by site (colorectal, colon) based on conventional (forward) two sample Mendelian randomization analyses with FADS variants excluded from metabolite instruments.</title><p>Estimates shown are ORs for colorectal cancer per SD metabolite. Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR &lt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87894-fig4-figsupp3-v1.tif"/></fig></fig-group><p>In anatomical subtype-stratified analyses, evidence was the strongest for an effect of fatty acid traits on higher CRC risk, and this appeared specific to the distal colon, for example, omega-3 (distal CRC OR = 1.20, 95% CI = 1.09–1.32), and ratio of DHA to total fatty acids (distal colon OR = 1.29, 95% CI = 1.16–1.43). There was also evidence of a negative effect of ratio of omega-6 to omega-3 fatty acids (distal CRC OR = 0.80, 95% CI = 0.74–0.88) and a positive effect of ratio of omega-3 fatty acids to total fatty acids (distal CRC = 1.24, 95% CI = 1.15–1.35; seen also for proximal CRC OR = 1.15, 95% CI = 1.07–1.23) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1j</xref>). These estimates were also directionally consistent in MR sensitivity models.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Here, we used a reverse MR framework to identify circulating metabolites which are associated with genetic CRC liability across different stages of the early life course and attempted to replicate results in an independent cohort of middle-aged adults. We then performed forward MR to characterize the causal direction of the relationship between metabolites and CRC. Our GRS analysis provided evidence for an association of genetic liability to CRC with higher circulating levels of lipoprotein lipids (including total cholesterol, VLDL-cholesterol, and LDL-cholesterol), apolipoproteins (including apolipoprotein B), and fatty acids (including omega-3 and DHA) in young adults. These results were largely consistent in direction (though smaller in magnitude and weaker in strength of evidence) in a two-sample MR analysis in an independent cohort of middle-aged adults. Results were attenuated, but consistent in direction, when potentially pleiotropic SNPs in the <italic>FADS</italic> gene regions were excluded. However, it should be noted that use of a narrow window for exclusion based on being within one of the three <italic>FADS</italic> genes may mean that some pleiotropic SNPs remain. Our subsequent forward MR analysis highlighted PUFAs as potentially having a causal role in the development of CRC.</p><p>Our analyses highlight a potentially important role of PUFAs in CRC liability. However, these analyses may be biased by substantial genetic pleiotropy among fatty acid traits. SNPs which are associated with levels of one fatty acid are generally associated with levels of many more fatty acid (and non-fatty acid) traits (<xref ref-type="bibr" rid="bib6">Borges et al., 2022b</xref>). For instance, genetic instruments within the FADS cluster of genes will likely affect both omega-3 and omega-6 fatty acids, given <italic>FADS1</italic> and <italic>FADS2</italic> encode enzymes which catalyze the conversion of both from shorter chain into longer chain fatty acids (<xref ref-type="bibr" rid="bib6">Borges et al., 2022b</xref>). In addition, the NMR metabolomics platform utilized in the analyses outlined here has limited coverage of fatty acids, meaning that many putative causal metabolites for CRC, for example, arachidonic acid, could not be investigated. Therefore, although our results indicate that PUFAs may be important in CRC risk, given the pleiotropic nature of the fatty acid genetic instruments and the limited coverage of the NMR platform, we are unable to determine with any certainty which specific classes of fatty acids may be driving these associations.</p><p>Our analyses featured evaluating the effect of genetic liability to CRC on circulating metabolites across repeated measures in the ALSPAC cohort. The mean ages at the time of the repeated measures were 8 y, 16 y, 18 y, and 25 y, representing childhood, early adolescence, late adolescence, and young adulthood, respectively, and therefore individuals in this cohort are unlikely to be taking metabolite-altering medication such as statins, and unlikely to have CRC. The strongest evidence for an effect of liability to CRC on metabolite levels was seen in late adolescence. The reason for this remains unclear. It is possible that this represents a true biological phenomenon if late adolescence is a critical window in CRC development or metabolite variability, which may be likely given the limited variance in metabolite levels at the later age of 25 y (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). The lack of an effect at the younger ages could be explained by the fact that the CRC GRS may capture many key life events or experiences which could impact the metabolome (e.g. initiation of smoking, higher category of BMI reached, educational attainment level set, etc.) but may not have yet happened at younger ages, thus obscuring an effect of genetic liability to CRC on the metabolome. Our results suggest that puberty could be important, with an effect seen seemingly particularly at the end of puberty. Repeating our analysis with sex-stratified data may aid in determining whether this is likely to be the case; sex-stratified GWAS for metabolites are not currently available to replicate such analyses. An alternative explanation is selection bias due to loss of follow-up, leading to a change in sample characteristics over time.</p><p>Another key finding in the reverse MR analysis was that genetic liability to CRC was associated with increased levels of total cholesterol, VLDL-cholesterol, LDL-cholesterol, and apolipoprotein B, though we find little evidence for a causal effect of these traits on risk of CRC in the forward MR, replicating previous forward MR analyses for total and LDL-cholesterol (<xref ref-type="bibr" rid="bib30">Gui et al., 2023</xref>; <xref ref-type="bibr" rid="bib68">Rodriguez-Broadbent et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Cornish et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Luo et al., 2021</xref>). This suggests that these traits may either be only predictive of (i.e. non-causal for) later CRC development or may be influenced by the development of CRC and could have diagnostic or predictive potential. Given that the participants in the ALSPAC cohort are many decades younger than the average age of diagnosis for CRC (mean age 25 y in the latest repeated measure analysed in ALSPAC; whereas the median age at diagnosis of CRC is 64 y) (<xref ref-type="bibr" rid="bib29">Granados-Romero et al., 2017</xref>), the former seems the most likely scenario. Previous conventional observational studies have presented conflicting results when investigating the association between measures of cholesterol and CRC risk, with some finding an inverse association and others a positive association, possibly reflecting residual confounding in conventional observational analyses (<xref ref-type="bibr" rid="bib62">Park et al., 2000</xref>; <xref ref-type="bibr" rid="bib79">Yang et al., 2022</xref>; <xref ref-type="bibr" rid="bib75">Tian et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Yao and Tian, 2015</xref>; <xref ref-type="bibr" rid="bib54">Mayengbam et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Mannes et al., 1986</xref>; <xref ref-type="bibr" rid="bib52">Mamtani et al., 2016</xref>). Previous MR studies have had similar findings to our forward MR analysis, in that there seems to be little evidence for a causal effect of cholesterol on CRC development (<xref ref-type="bibr" rid="bib68">Rodriguez-Broadbent et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Cornish et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Luo et al., 2021</xref>). One possible explanation for how circulating levels of total cholesterol, VLDL-cholesterol, LDL-cholesterol, and apolipoprotein B could predict (without necessarily causing) future CRC development could be linked to diet. A previous MR analysis suggested an effect of increased BMI on several measures of circulating cholesterol (<xref ref-type="bibr" rid="bib30">Gui et al., 2023</xref>). Consuming a diet which is high in fat may increase CRC risk both through and possibly independently of adiposity, alongside increasing levels of circulating cholesterol (<xref ref-type="bibr" rid="bib60">Ocvirk et al., 2019</xref>; <xref ref-type="bibr" rid="bib74">Tang et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Bell and Culp, 2022</xref>; <xref ref-type="bibr" rid="bib15">Chiu et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Han et al., 2018</xref>; <xref ref-type="bibr" rid="bib76">Vincent et al., 2019</xref>). The potential for lipoprotein or apolipoprotein lipid measures in future CRC risk prediction should be further investigated.</p><p>Our analyses stratified by anatomical subsite highlighted fatty acids as being affected by genetic liability to colon and proximal colon cancer, with the forward MR confirming that fatty acid traits may be particularly important in the development of these subsites of CRC as well as distal colon cancer.</p><p>In our forward MR analyses, we were unable to replicate the findings of three previous MR studies which found evidence for a causal effect of circulating linoleic acid levels on CRC development in terms of strength of evidence, though the direction of the effect estimate was similar to previous studies (<xref ref-type="bibr" rid="bib55">May Wilson et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Khankari et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Liyanage et al., 2019</xref>). This is surprising as all three previous analyses had a much smaller sample size than that included in our analysis (the largest had sample size of 24,748 for exposure vs 118,466 presently; and 11,016 cases and 13,732 controls for outcome vs 52,775 cases and 45,940 controls presently). Our analysis using updated genetic instruments to proxy fatty acids may be more successful in accurately instrumenting heterogenous phenotypes such as metabolite levels compared with previous analyses. All other findings in our forward MR analysis are consistent with previous MR studies where they exist (<xref ref-type="bibr" rid="bib68">Rodriguez-Broadbent et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Cornish et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Luo et al., 2021</xref>).</p><sec id="s4-1"><title>Limitations</title><p>The limitations of this study include firstly the relatively small sample size included in the ALSPAC analysis, which may have implications for power and precision. Secondly, mostly due to the longitudinal nature of the ALSPAC study, our sample at each time point is composed of slightly different individuals. This could be influencing our results and should be taken into account when comparing across time points. Thirdly, our analyses involving genetic instruments for CRC liability may have suffered from horizontal pleiotropy, even after excluding genetic variants in or near the <italic>FADS</italic> gene. Fourthly, our analyses were mostly restricted to white Europeans, which limits the generalizability of our findings to other populations. Fifthly, our analysis would benefit from being repeated with sex-stratified data. Although such GWAS results for metabolites are not currently available, the data to perform such GWAS are available in UK Biobank for future analyses. Sixthly, for our forward MR analysis, we used the UK Biobank for our exposure data. The UK Biobank has a median age of 58 at the time these measurements were taken, meaning statin use may be widespread in this population, which could be attenuating our effect estimates. Future work could attempt to replicate our analysis in a population with lower prevalence of statins intake. Finally, we included only metabolites measured using NMR. Confirming whether our results replicate using metabolite data measured with an alternative method would strengthen our findings.</p></sec><sec id="s4-2"><title>Conclusions</title><p>Our analysis provides evidence that genetic liability to CRC is associated with altered levels of metabolites at certain ages, some of which may have a causal role in CRC development. Further investigating the role of PUFAs in CRC risk and circulating cholesterol in CRC prediction may be promising avenues for future research.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Funding acquisition, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Written informed consent was obtained for all study participants. Ethical approval was obtained from the ALSPAC Law and Ethics Committee and the local research ethics committee (proposal B3538). Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Ethics for the CRC GWAS were approved by respective institutional review boards.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables.</title><p>(<bold>a</bold>) Genetic variants used to construct genetic risk scores reflecting colorectal cancer liability. (<bold>b</bold>) Mean and SD values for raw metabolic traits at different life stages among ALSPAC offspring. (<bold>c</bold>) Associations of genetic liability to colorectal cancer with metabolic traits at different early life stages among ALSPAC offspring. (<bold>d</bold>) Associations of genetic liability to colorectal cancer (excluding SNPs in the FADS gene region) with metabolic traits at different early life stages among ALSPAC offspring. (<bold>e</bold>) Assessment of instrument strength for MR analyses. (<bold>f</bold>) Associations of genetic liability to colorectal cancer with metabolic traits based on two-sample MR. (<bold>g</bold>) Associations of genetic liability to colorectal cancer with metabolic traits based on two-sample MR, excluding variants in the FADS gene region. (<bold>h</bold>) Genetic variants used to instrument circulating metabolites. (<bold>i</bold>) Assessment of instrument strength for MR analyses. (<bold>j</bold>) Estimated effects of circulating metabolites on colorectal cancer risk based on two-sample MR. (<bold>k</bold>) Estimated effects of circulating metabolites on colorectal cancer risk based on two-sample MR, excluding variants in the FADS gene region.</p></caption><media xlink:href="elife-87894-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87894-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated during this study are included in the manuscript and supporting file. Access to individual-level ALSPAC data are available following an application. The summary-level GWAS data for CRC used in this study are available following an application to GECCO (managed access). All data generated by this study are available in the manuscript and supporting material. R scripts used in this study have been made publicly available on GitHub at: <ext-link ext-link-type="uri" xlink:href="https://github.com/cb12104/adiposity_metabolites_crc">https://github.com/cb12104/adiposity_metabolites_crc</ext-link>, (copy archived at <xref ref-type="bibr" rid="bib9">Bull, 2020</xref>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. EPICOLON: We are sincerely grateful to all patients participating in this study who were recruited as part of the EPICOLON project. We acknowledge the Spanish National DNA Bank, Biobank of Hospital Clínic–IDIBAPS, and Biobanco Vasco for the availability of the samples. The work was carried out (in part) at the Esther Koplowitz Centre, Barcelona. JAB is supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z) and works in a Unit funded by the Medical Research Council (MC_UU_00011/1) and the University of Bristol. EEV, DNL, and CB are supported by Diabetes UK (17/0005587). NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC &amp; WT 102215/2/13/2), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit (MC_UU_00011/1), and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). EH is supported by a Cancer Research UK Population Research Committee Studentship (C18281/A30905), is supported by the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019), and is part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00011/4) and the University of Bristol. AC acknowledges funding from grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff, and Exeter from the Medical Research Council (MRC)/UKRI. MCB is supported by the UK Medical Research Council (MRC) Skills Development Fellowship (MR/P014054/1), University of Bristol Vice-Chancellor’s Fellowship, and MRC Integrative Epidemiology Unit (MC_UU_00011/6). This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol: <ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/acrc/">http://www.bristol.ac.uk/acrc/</ext-link>. For study funding, please see Appendix 1.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Hammar</surname><given-names>U</given-names></name><name><surname>Kennedy</surname><given-names>B</given-names></name><name><surname>Salihovic</surname><given-names>S</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Sundström</surname><given-names>J</given-names></name><name><surname>Ärnlöv</surname><given-names>J</given-names></name><name><surname>Berne</surname><given-names>C</given-names></name><name><surname>Risérus</surname><given-names>U</given-names></name><name><surname>Magnusson</surname><given-names>PKE</given-names></name><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Fall</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effect of general adiposity and central body fat distribution on the circulating metabolome: a multicohort nontargeted metabolomics observational and mendelian randomization study</article-title><source>Diabetes</source><volume>71</volume><fpage>329</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.2337/db20-1120</pub-id><pub-id pub-id-type="pmid">34785567</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>AE</given-names></name><name><surname>Culp</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Reduction insaturated fat intake for cardiovascular disease</article-title><source>American Family Physician</source><volume>105</volume><elocation-id>CD011737</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD011737</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertini</surname><given-names>I</given-names></name><name><surname>Cacciatore</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>BV</given-names></name><name><surname>Schou</surname><given-names>JV</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Kruhøffer</surname><given-names>M</given-names></name><name><surname>Luchinat</surname><given-names>C</given-names></name><name><surname>Nielsen</surname><given-names>DL</given-names></name><name><surname>Turano</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>356</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1543</pub-id><pub-id pub-id-type="pmid">22080567</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>MC</given-names></name><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants</article-title><source>BMC Medicine</source><volume>20</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-022-02399-w</pub-id><pub-id pub-id-type="pmid">35692035</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>MC</given-names></name><name><surname>Haycock</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Howe</surname><given-names>LJ</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Staley</surname><given-names>JR</given-names></name><name><surname>Lumbers</surname><given-names>RT</given-names></name><name><surname>Henry</surname><given-names>A</given-names></name><name><surname>Lemaitre</surname><given-names>RN</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in Europeans and East Asians: a Mendelian randomization study</article-title><source>Human Molecular Genetics</source><volume>31</volume><fpage>4034</fpage><lpage>4054</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddac153</pub-id><pub-id pub-id-type="pmid">35796550</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator</article-title><source>Genetic Epidemiology</source><volume>40</volume><fpage>304</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1002/gepi.21965</pub-id><pub-id pub-id-type="pmid">27061298</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Golding</surname><given-names>J</given-names></name><name><surname>Macleod</surname><given-names>J</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Fraser</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Molloy</surname><given-names>L</given-names></name><name><surname>Ness</surname><given-names>A</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cohort Profile: the ’children of the 90s’--the index offspring of the Avon Longitudinal Study of Parents and Children</article-title><source>International Journal of Epidemiology</source><volume>42</volume><fpage>111</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/ije/dys064</pub-id><pub-id pub-id-type="pmid">22507743</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Adiposity_Metabolites_Crc</data-title><version designator="swh:1:rev:9cb9fc22ab705c6d6f03e105bd6074962410d32a">swh:1:rev:9cb9fc22ab705c6d6f03e105bd6074962410d32a</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:289ef5cb465623cf0633fc583d28f3a76705773c;origin=https://github.com/cb12104/adiposity_metabolites_crc;visit=swh:1:snp:d190e8d447b6dc2132c7699664b402d612a3a39f;anchor=swh:1:rev:9cb9fc22ab705c6d6f03e105bd6074962410d32a">https://archive.softwareheritage.org/swh:1:dir:289ef5cb465623cf0633fc583d28f3a76705773c;origin=https://github.com/cb12104/adiposity_metabolites_crc;visit=swh:1:snp:d190e8d447b6dc2132c7699664b402d612a3a39f;anchor=swh:1:rev:9cb9fc22ab705c6d6f03e105bd6074962410d32a</ext-link></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>NM</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bias due to participant overlap in two-sample Mendelian randomization</article-title><source>Genetic Epidemiology</source><volume>40</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1002/gepi.21998</pub-id><pub-id pub-id-type="pmid">27625185</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Labrecque</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates</article-title><source>European Journal of Epidemiology</source><volume>33</volume><fpage>947</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1007/s10654-018-0424-6</pub-id><pub-id pub-id-type="pmid">30039250</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bycroft</surname><given-names>C</given-names></name><name><surname>Freeman</surname><given-names>C</given-names></name><name><surname>Petkova</surname><given-names>D</given-names></name><name><surname>Band</surname><given-names>G</given-names></name><name><surname>Elliott</surname><given-names>LT</given-names></name><name><surname>Sharp</surname><given-names>K</given-names></name><name><surname>Motyer</surname><given-names>A</given-names></name><name><surname>Vukcevic</surname><given-names>D</given-names></name><name><surname>Delaneau</surname><given-names>O</given-names></name><name><surname>O’Connell</surname><given-names>J</given-names></name><name><surname>Cortes</surname><given-names>A</given-names></name><name><surname>Welsh</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Effingham</surname><given-names>M</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Leslie</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>N</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name><name><surname>Marchini</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The UK Biobank resource with deep phenotyping and genomic data</article-title><source>Nature</source><volume>562</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmid">30305743</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Heisser</surname><given-names>T</given-names></name><name><surname>Hackl</surname><given-names>M</given-names></name><name><surname>Ihle</surname><given-names>P</given-names></name><name><surname>De Schutter</surname><given-names>H</given-names></name><name><surname>Van Damme</surname><given-names>N</given-names></name><name><surname>Valerianova</surname><given-names>Z</given-names></name><name><surname>Atanasov</surname><given-names>T</given-names></name><name><surname>Májek</surname><given-names>O</given-names></name><name><surname>Mužík</surname><given-names>J</given-names></name><name><surname>Nilbert</surname><given-names>MC</given-names></name><name><surname>Tybjerg</surname><given-names>AJ</given-names></name><name><surname>Innos</surname><given-names>K</given-names></name><name><surname>Mägi</surname><given-names>M</given-names></name><name><surname>Malila</surname><given-names>N</given-names></name><name><surname>Bouvier</surname><given-names>AM</given-names></name><name><surname>Bouvier</surname><given-names>V</given-names></name><name><surname>Launoy</surname><given-names>G</given-names></name><name><surname>Woronoff</surname><given-names>AS</given-names></name><name><surname>Cariou</surname><given-names>M</given-names></name><name><surname>Robaszkiewicz</surname><given-names>M</given-names></name><name><surname>Delafosse</surname><given-names>P</given-names></name><name><surname>Poncet</surname><given-names>F</given-names></name><name><surname>Katalinic</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>PM</given-names></name><name><surname>Senore</surname><given-names>C</given-names></name><name><surname>Rosso</surname><given-names>S</given-names></name><name><surname>Vincerževskienė</surname><given-names>I</given-names></name><name><surname>Lemmens</surname><given-names>V</given-names></name><name><surname>Elferink</surname><given-names>MAG</given-names></name><name><surname>Johannesen</surname><given-names>TB</given-names></name><name><surname>Kørner</surname><given-names>H</given-names></name><name><surname>Pfeffer</surname><given-names>F</given-names></name><name><surname>Bento</surname><given-names>MJ</given-names></name><name><surname>Rodrigues</surname><given-names>J</given-names></name><name><surname>Alves da Costa</surname><given-names>F</given-names></name><name><surname>Miranda</surname><given-names>A</given-names></name><name><surname>Zadnik</surname><given-names>V</given-names></name><name><surname>Žagar</surname><given-names>T</given-names></name><name><surname>Lopez de Munain Marques</surname><given-names>A</given-names></name><name><surname>Marcos-Gragera</surname><given-names>R</given-names></name><name><surname>Puigdemont</surname><given-names>M</given-names></name><name><surname>Galceran</surname><given-names>J</given-names></name><name><surname>Carulla</surname><given-names>M</given-names></name><name><surname>Chirlaque</surname><given-names>MD</given-names></name><name><surname>Ballesta</surname><given-names>M</given-names></name><name><surname>Sundquist</surname><given-names>K</given-names></name><name><surname>Sundquist</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>A</given-names></name><name><surname>Herrmann</surname><given-names>C</given-names></name><name><surname>Mousavi</surname><given-names>M</given-names></name><name><surname>Ryzhov</surname><given-names>A</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study</article-title><source>The Lancet. Oncology</source><volume>22</volume><fpage>1002</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00199-6</pub-id><pub-id pub-id-type="pmid">34048685</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Cairns</surname><given-names>BJ</given-names></name><name><surname>Small</surname><given-names>AM</given-names></name><name><surname>Burr</surname><given-names>HA</given-names></name><name><surname>Ambikkumar</surname><given-names>A</given-names></name><name><surname>Martinsson</surname><given-names>A</given-names></name><name><surname>Thériault</surname><given-names>S</given-names></name><name><surname>Munter</surname><given-names>HM</given-names></name><name><surname>Steffen</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Levinson</surname><given-names>RT</given-names></name><name><surname>Shaffer</surname><given-names>CM</given-names></name><name><surname>Rong</surname><given-names>J</given-names></name><name><surname>Sonestedt</surname><given-names>E</given-names></name><name><surname>Dufresne</surname><given-names>L</given-names></name><name><surname>Ljungberg</surname><given-names>J</given-names></name><name><surname>Näslund</surname><given-names>U</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Ranatunga</surname><given-names>DK</given-names></name><name><surname>Whitmer</surname><given-names>RA</given-names></name><name><surname>Budoff</surname><given-names>MJ</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Harris</surname><given-names>WS</given-names></name><name><surname>Damrauer</surname><given-names>SM</given-names></name><name><surname>Stark</surname><given-names>KD</given-names></name><name><surname>Boekholdt</surname><given-names>SM</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>Arsenault</surname><given-names>BJ</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Tsai</surname><given-names>MY</given-names></name><name><surname>Post</surname><given-names>WS</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Söderberg</surname><given-names>S</given-names></name><name><surname>Bossé</surname><given-names>Y</given-names></name><name><surname>Wells</surname><given-names>QS</given-names></name><name><surname>Smith</surname><given-names>JG</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Engert</surname><given-names>JC</given-names></name><name><surname>Thanassoulis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association of FADS1/2 locus variants and polyunsaturated fatty acids with aortic stenosis</article-title><source>JAMA Cardiology</source><volume>5</volume><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2020.0246</pub-id><pub-id pub-id-type="pmid">32186652</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>PT</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Catapano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of A very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0170664</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0170664</pub-id><pub-id pub-id-type="pmid">28166253</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>GL</given-names></name><name><surname>Borges</surname><given-names>MC</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>From Menarche to Menopause: The Impact of Reproductive Factors on the Metabolic Profile of over 65,000 Women</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2022.04.17.22273947</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="web"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><year iso-8601-date="2022">2022</year><article-title>TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial. - Full Text View</article-title><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02980029">https://clinicaltrials.gov/ct2/show/NCT02980029</ext-link><date-in-citation iso-8601-date="2023-11-22">November 22, 2023</date-in-citation></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clinton</surname><given-names>SK</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>Hursting</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>World cancer research fund/american institute for cancer research: continuous update project expert report: diet, nutrition, physical activity and colorectal cancer</article-title><source>The Journal of Nutrition</source><volume>150</volume><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1093/jn/nxz268</pub-id><pub-id pub-id-type="pmid">7317613</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornish</surname><given-names>AJ</given-names></name><name><surname>Law</surname><given-names>PJ</given-names></name><name><surname>Timofeeva</surname><given-names>M</given-names></name><name><surname>Palin</surname><given-names>K</given-names></name><name><surname>Farrington</surname><given-names>SM</given-names></name><name><surname>Palles</surname><given-names>C</given-names></name><name><surname>Jenkins</surname><given-names>MA</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Kirac</surname><given-names>I</given-names></name><name><surname>Maughan</surname><given-names>T</given-names></name><name><surname>Brezina</surname><given-names>S</given-names></name><name><surname>Gsur</surname><given-names>A</given-names></name><name><surname>Cheadle</surname><given-names>JP</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Tomlinson</surname><given-names>I</given-names></name><name><surname>Dunlop</surname><given-names>MG</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Modifiable pathways for colorectal cancer: a mendelian randomisation analysis</article-title><source>The Lancet. Gastroenterology &amp; Hepatology</source><volume>5</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(19)30294-8</pub-id><pub-id pub-id-type="pmid">31668584</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czene</surname><given-names>K</given-names></name><name><surname>Lichtenstein</surname><given-names>P</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database</article-title><source>International Journal of Cancer</source><volume>99</volume><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1002/ijc.10332</pub-id><pub-id pub-id-type="pmid">11979442</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Data.bris</collab></person-group><year iso-8601-date="2022">2022</year><article-title>MRC IEU UK Biobank GWAS pipeline version 2 - Datasets</article-title><ext-link ext-link-type="uri" xlink:href="https://data.bris.ac.uk/data/dataset/pnoat8cxo0u52p6ynfaekeigi">https://data.bris.ac.uk/data/dataset/pnoat8cxo0u52p6ynfaekeigi</ext-link><date-in-citation iso-8601-date="2022-10-14">October 14, 2022</date-in-citation></element-citation></ref><ref id="bib22"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Elsworth</surname><given-names>B</given-names></name><name><surname>Lyon</surname><given-names>M</given-names></name><name><surname>Alexander</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Matthews</surname><given-names>P</given-names></name><name><surname>Hallett</surname><given-names>J</given-names></name><name><surname>Bates</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>T</given-names></name><name><surname>Haberland</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Haycock</surname><given-names>P</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The MRC IEU OpenGWAS Data Infrastructure</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.08.10.244293</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farshidfar</surname><given-names>F</given-names></name><name><surname>Weljie</surname><given-names>AM</given-names></name><name><surname>Kopciuk</surname><given-names>K</given-names></name><name><surname>Buie</surname><given-names>WD</given-names></name><name><surname>Maclean</surname><given-names>A</given-names></name><name><surname>Dixon</surname><given-names>E</given-names></name><name><surname>Sutherland</surname><given-names>FR</given-names></name><name><surname>Molckovsky</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Bathe</surname><given-names>OF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Serum metabolomic profile as a means to distinguish stage of colorectal cancer</article-title><source>Genome Medicine</source><volume>4</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/gm341</pub-id><pub-id pub-id-type="pmid">22583555</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farshidfar</surname><given-names>F</given-names></name><name><surname>Weljie</surname><given-names>AM</given-names></name><name><surname>Kopciuk</surname><given-names>KA</given-names></name><name><surname>Hilsden</surname><given-names>R</given-names></name><name><surname>McGregor</surname><given-names>SE</given-names></name><name><surname>Buie</surname><given-names>WD</given-names></name><name><surname>MacLean</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Bathe</surname><given-names>OF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics</article-title><source>British Journal of Cancer</source><volume>115</volume><fpage>848</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.243</pub-id><pub-id pub-id-type="pmid">27560555</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Rebelo</surname><given-names>M</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title><source>International Journal of Cancer</source><volume>136</volume><fpage>E359</fpage><lpage>E386</lpage><pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id><pub-id pub-id-type="pmid">25220842</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fhu</surname><given-names>CW</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fatty acid synthase: an emerging target in cancer</article-title><source>Molecules</source><volume>25</volume><elocation-id>3935</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25173935</pub-id><pub-id pub-id-type="pmid">32872164</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>A</given-names></name><name><surname>Macdonald-Wallis</surname><given-names>C</given-names></name><name><surname>Tilling</surname><given-names>K</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Golding</surname><given-names>J</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Macleod</surname><given-names>J</given-names></name><name><surname>Molloy</surname><given-names>L</given-names></name><name><surname>Ness</surname><given-names>A</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>SM</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cohort Profile: the avon longitudinal study of parents and children: ALSPAC mothers cohort</article-title><source>International Journal of Epidemiology</source><volume>42</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1093/ije/dys066</pub-id><pub-id pub-id-type="pmid">22507742</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Reply</article-title><source>Gastroenterology</source><volume>164</volume><fpage>701</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2022.11.033</pub-id><pub-id pub-id-type="pmid">36481195</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granados-Romero</surname><given-names>JJ</given-names></name><name><surname>Valderrama-Treviño</surname><given-names>AI</given-names></name><name><surname>Contreras-Flores</surname><given-names>EH</given-names></name><name><surname>Barrera-Mera</surname><given-names>B</given-names></name><name><surname>Herrera Enríquez</surname><given-names>M</given-names></name><name><surname>Uriarte-Ruíz</surname><given-names>K</given-names></name><name><surname>Ceballos-Villalba</surname><given-names>JC</given-names></name><name><surname>Estrada-Mata</surname><given-names>AG</given-names></name><name><surname>Alvarado Rodríguez</surname><given-names>C</given-names></name><name><surname>Arauz-Peña</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Colorectal cancer: a review</article-title><source>International Journal of Research in Medical Sciences</source><volume>5</volume><elocation-id>4667</elocation-id><pub-id pub-id-type="doi">10.18203/2320-6012.ijrms20174914</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Pi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Obesity and head and neck cancer risk: a mendelian randomization study</article-title><source>BMC Medical Genomics</source><volume>16</volume><elocation-id>200</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-023-01634-4</pub-id><pub-id pub-id-type="pmid">37620971</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Yeung</surname><given-names>SC</given-names></name><name><surname>Ip</surname><given-names>MSM</given-names></name><name><surname>Mak</surname><given-names>JCW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dysregulation of cardiac lipid parameters in high-fat high-cholesterol diet-induced rat model</article-title><source>Lipids in Health and Disease</source><volume>17</volume><elocation-id>255</elocation-id><pub-id pub-id-type="doi">10.1186/s12944-018-0905-3</pub-id><pub-id pub-id-type="pmid">30428911</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Händel</surname><given-names>MN</given-names></name><name><surname>Rohde</surname><given-names>JF</given-names></name><name><surname>Jacobsen</surname><given-names>R</given-names></name><name><surname>Nielsen</surname><given-names>SM</given-names></name><name><surname>Christensen</surname><given-names>R</given-names></name><name><surname>Alexander</surname><given-names>DD</given-names></name><name><surname>Frederiksen</surname><given-names>P</given-names></name><name><surname>Heitmann</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Processed meat intake and incidence of colorectal cancer: a systematic review and meta-analysis of prospective observational studies</article-title><source>European Journal of Clinical Nutrition</source><volume>74</volume><fpage>1132</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1038/s41430-020-0576-9</pub-id><pub-id pub-id-type="pmid">32029911</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Thielke</surname><given-names>R</given-names></name><name><surname>Payne</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>N</given-names></name><name><surname>Conde</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support</article-title><source>Journal of Biomedical Informatics</source><volume>42</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwig</surname><given-names>FP</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption</article-title><source>International Journal of Epidemiology</source><volume>46</volume><fpage>1985</fpage><lpage>1998</lpage><pub-id pub-id-type="doi">10.1093/ije/dyx102</pub-id><pub-id pub-id-type="pmid">29040600</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Borges</surname><given-names>MC</given-names></name><name><surname>Burrows</surname><given-names>K</given-names></name><name><surname>Lemaitre</surname><given-names>RN</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Khankari</surname><given-names>NK</given-names></name><name><surname>Tsilidis</surname><given-names>KK</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Truong</surname><given-names>T</given-names></name><name><surname>Birmann</surname><given-names>BM</given-names></name><name><surname>OMara</surname><given-names>T</given-names></name><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Iles</surname><given-names>MM</given-names></name><name><surname>Law</surname><given-names>MH</given-names></name><name><surname>Slager</surname><given-names>SL</given-names></name><name><surname>Saberi Hosnijeh</surname><given-names>F</given-names></name><name><surname>Mariosa</surname><given-names>D</given-names></name><name><surname>Cotterchio</surname><given-names>M</given-names></name><name><surname>Cerhan</surname><given-names>JR</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Enroth</surname><given-names>S</given-names></name><name><surname>Gharahkhani</surname><given-names>P</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>AC</given-names></name><name><surname>Block</surname><given-names>RC</given-names></name><collab>ACCC</collab><collab>CCFR-CORECT-GECCO</collab><collab>EPITHYR</collab><collab>InterLymph</collab><collab>MMAC</collab><collab>ECAC</collab><collab>ILCCO</collab><collab>PRACTICAL Consortium</collab><collab>PanScan</collab><collab>PanC4</collab><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Relton</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><collab>Fatty Acids in Cancer Mendelian Randomization Collaboration</collab></person-group><year iso-8601-date="2023">2023</year><article-title>The association between genetically elevated polyunsaturated fatty acids and risk of cancer</article-title><source>EBioMedicine</source><volume>91</volume><elocation-id>104510</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104510</pub-id><pub-id pub-id-type="pmid">37086649</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Wade</surname><given-names>KH</given-names></name><name><surname>Laurin</surname><given-names>C</given-names></name><name><surname>Elsworth</surname><given-names>B</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Langdon</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>V</given-names></name><name><surname>Yarmolinsky</surname><given-names>J</given-names></name><name><surname>Shihab</surname><given-names>HA</given-names></name><name><surname>Timpson</surname><given-names>N</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Relton</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Haycock</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/078972</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Elsworth</surname><given-names>B</given-names></name><name><surname>Wade</surname><given-names>KH</given-names></name><name><surname>Haberland</surname><given-names>V</given-names></name><name><surname>Baird</surname><given-names>D</given-names></name><name><surname>Laurin</surname><given-names>C</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Langdon</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>VY</given-names></name><name><surname>Yarmolinsky</surname><given-names>J</given-names></name><name><surname>Shihab</surname><given-names>HA</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Relton</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Haycock</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The MR-Base platform supports systematic causal inference across the human phenome</article-title><source>eLife</source><volume>7</volume><elocation-id>e34408</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34408</pub-id><pub-id pub-id-type="pmid">29846171</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Can mendelian randomization shift into reverse gear?</article-title><source>Clinical Chemistry</source><volume>65</volume><fpage>363</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2018.296806</pub-id><pub-id pub-id-type="pmid">30692117</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huyghe</surname><given-names>JR</given-names></name><name><surname>Bien</surname><given-names>SA</given-names></name><name><surname>Harrison</surname><given-names>TA</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Schmit</surname><given-names>SL</given-names></name><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Jeon</surname><given-names>J</given-names></name><name><surname>Edlund</surname><given-names>CK</given-names></name><name><surname>Greenside</surname><given-names>P</given-names></name><name><surname>Wainberg</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>FR</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Levine</surname><given-names>DM</given-names></name><name><surname>Nelson</surname><given-names>SC</given-names></name><name><surname>Sinnott-Armstrong</surname><given-names>NA</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>MH</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Arnau-Collell</surname><given-names>C</given-names></name><name><surname>Arndt</surname><given-names>V</given-names></name><name><surname>Bamia</surname><given-names>C</given-names></name><name><surname>Banbury</surname><given-names>BL</given-names></name><name><surname>Baron</surname><given-names>JA</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Bézieau</surname><given-names>S</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Boehm</surname><given-names>J</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Brezina</surname><given-names>S</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Buchanan</surname><given-names>DD</given-names></name><name><surname>Burnett-Hartman</surname><given-names>A</given-names></name><name><surname>Butterbach</surname><given-names>K</given-names></name><name><surname>Caan</surname><given-names>BJ</given-names></name><name><surname>Campbell</surname><given-names>PT</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Castellví-Bel</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Chirlaque</surname><given-names>M-D</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Connolly</surname><given-names>CM</given-names></name><name><surname>Cross</surname><given-names>AJ</given-names></name><name><surname>Cuk</surname><given-names>K</given-names></name><name><surname>Curtis</surname><given-names>KR</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Duggan</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Elias</surname><given-names>SG</given-names></name><name><surname>Elliott</surname><given-names>F</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Feskens</surname><given-names>EJM</given-names></name><name><surname>Figueiredo</surname><given-names>JC</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>FitzGerald</surname><given-names>LM</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Gala</surname><given-names>M</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Gauderman</surname><given-names>WJ</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Gillanders</surname><given-names>E</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Grady</surname><given-names>WM</given-names></name><name><surname>Grove</surname><given-names>JS</given-names></name><name><surname>Gsur</surname><given-names>A</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Haile</surname><given-names>RW</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Harlid</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Hofer</surname><given-names>P</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Hsu</surname><given-names>W-L</given-names></name><name><surname>Huang</surname><given-names>W-Y</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Ibañez-Sanz</surname><given-names>G</given-names></name><name><surname>Idos</surname><given-names>GE</given-names></name><name><surname>Ingersoll</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>RD</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Jenkins</surname><given-names>MA</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Joshu</surname><given-names>CE</given-names></name><name><surname>Keku</surname><given-names>TO</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Kobayashi</surname><given-names>E</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Kühn</surname><given-names>T</given-names></name><name><surname>Küry</surname><given-names>S</given-names></name><name><surname>Kweon</surname><given-names>S-S</given-names></name><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Laurie</surname><given-names>CA</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Leal</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Lejbkowicz</surname><given-names>F</given-names></name><name><surname>Lemire</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>CI</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lieb</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Louie</surname><given-names>TL</given-names></name><name><surname>Männistö</surname><given-names>S</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Martín</surname><given-names>V</given-names></name><name><surname>Masala</surname><given-names>G</given-names></name><name><surname>McNeil</surname><given-names>CE</given-names></name><name><surname>Melas</surname><given-names>M</given-names></name><name><surname>Milne</surname><given-names>RL</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Myte</surname><given-names>R</given-names></name><name><surname>Naccarati</surname><given-names>A</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Onland-Moret</surname><given-names>NC</given-names></name><name><surname>Pardini</surname><given-names>B</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Pearlman</surname><given-names>R</given-names></name><name><surname>Perduca</surname><given-names>V</given-names></name><name><surname>Pharoah</surname><given-names>PDP</given-names></name><name><surname>Pinchev</surname><given-names>M</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Prentice</surname><given-names>RL</given-names></name><name><surname>Pugh</surname><given-names>E</given-names></name><name><surname>Raskin</surname><given-names>L</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Rennert</surname><given-names>HS</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Rodríguez-Barranco</surname><given-names>M</given-names></name><name><surname>Romm</surname><given-names>J</given-names></name><name><surname>Sakoda</surname><given-names>LC</given-names></name><name><surname>Schafmayer</surname><given-names>C</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Seminara</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Shelford</surname><given-names>T</given-names></name><name><surname>Shin</surname><given-names>M-H</given-names></name><name><surname>Shulman</surname><given-names>K</given-names></name><name><surname>Sieri</surname><given-names>S</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>Stadler</surname><given-names>ZK</given-names></name><name><surname>Stegmaier</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>Y-R</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Thomas</surname><given-names>DC</given-names></name><name><surname>Thomas</surname><given-names>SS</given-names></name><name><surname>Toland</surname><given-names>AE</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>van Duijnhoven</surname><given-names>FJB</given-names></name><name><surname>Van Guelpen</surname><given-names>B</given-names></name><name><surname>van Kranen</surname><given-names>H</given-names></name><name><surname>Vijai</surname><given-names>J</given-names></name><name><surname>Visvanathan</surname><given-names>K</given-names></name><name><surname>Vodicka</surname><given-names>P</given-names></name><name><surname>Vodickova</surname><given-names>L</given-names></name><name><surname>Vymetalkova</surname><given-names>V</given-names></name><name><surname>Weigl</surname><given-names>K</given-names></name><name><surname>Weinstein</surname><given-names>SJ</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Win</surname><given-names>AK</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Woods</surname><given-names>MO</given-names></name><name><surname>Wu</surname><given-names>AH</given-names></name><name><surname>Zaidi</surname><given-names>SH</given-names></name><name><surname>Zanke</surname><given-names>BW</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Potter</surname><given-names>JD</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Gruber</surname><given-names>SB</given-names></name><name><surname>Hsu</surname><given-names>L</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discovery of common and rare genetic risk variants for colorectal cancer</article-title><source>Nature Genetics</source><volume>51</volume><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0286-6</pub-id><pub-id pub-id-type="pmid">30510241</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huyghe</surname><given-names>JR</given-names></name><name><surname>Harrison</surname><given-names>TA</given-names></name><name><surname>Bien</surname><given-names>SA</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Figueiredo</surname><given-names>JC</given-names></name><name><surname>Schmit</surname><given-names>SL</given-names></name><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Barfield</surname><given-names>R</given-names></name><name><surname>Baron</surname><given-names>JA</given-names></name><name><surname>Cross</surname><given-names>AJ</given-names></name><name><surname>Diergaarde</surname><given-names>B</given-names></name><name><surname>Duggan</surname><given-names>D</given-names></name><name><surname>Harlid</surname><given-names>S</given-names></name><name><surname>Imaz</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Levine</surname><given-names>DM</given-names></name><name><surname>Perduca</surname><given-names>V</given-names></name><name><surname>Perez-Cornago</surname><given-names>A</given-names></name><name><surname>Sakoda</surname><given-names>LC</given-names></name><name><surname>Schumacher</surname><given-names>FR</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name><name><surname>Toland</surname><given-names>AE</given-names></name><name><surname>van Duijnhoven</surname><given-names>FJB</given-names></name><name><surname>Van Guelpen</surname><given-names>B</given-names></name><name><surname>Agudo</surname><given-names>A</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>MH</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Arnau-Collell</surname><given-names>C</given-names></name><name><surname>Arndt</surname><given-names>V</given-names></name><name><surname>Banbury</surname><given-names>BL</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Bézieau</surname><given-names>S</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Boehm</surname><given-names>J</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Boutron-Ruault</surname><given-names>M-C</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Brezina</surname><given-names>S</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Buchanan</surname><given-names>DD</given-names></name><name><surname>Burnett-Hartman</surname><given-names>A</given-names></name><name><surname>Caan</surname><given-names>BJ</given-names></name><name><surname>Campbell</surname><given-names>PT</given-names></name><name><surname>Carr</surname><given-names>PR</given-names></name><name><surname>Castells</surname><given-names>A</given-names></name><name><surname>Castellví-Bel</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Curtis</surname><given-names>KR</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Feskens</surname><given-names>EJM</given-names></name><name><surname>Gala</surname><given-names>M</given-names></name><name><surname>Gallinger</surname><given-names>SJ</given-names></name><name><surname>Gauderman</surname><given-names>WJ</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Grady</surname><given-names>WM</given-names></name><name><surname>Grove</surname><given-names>JS</given-names></name><name><surname>Gsur</surname><given-names>A</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Haile</surname><given-names>RW</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Hsu</surname><given-names>W-L</given-names></name><name><surname>Huang</surname><given-names>W-Y</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Jenab</surname><given-names>M</given-names></name><name><surname>Jenkins</surname><given-names>MA</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Keku</surname><given-names>TO</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Kühn</surname><given-names>T</given-names></name><name><surname>Küry</surname><given-names>S</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Lejbkowicz</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>CI</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lieb</surname><given-names>W</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Männistö</surname><given-names>S</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Milne</surname><given-names>RL</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Nassir</surname><given-names>R</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Pearlman</surname><given-names>R</given-names></name><name><surname>Pharoah</surname><given-names>PDP</given-names></name><name><surname>Phipps</surname><given-names>AI</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Potter</surname><given-names>JD</given-names></name><name><surname>Prentice</surname><given-names>RL</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Raskin</surname><given-names>L</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Rennert</surname><given-names>HS</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Schafmayer</surname><given-names>C</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Seminara</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>Y-R</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Thomas</surname><given-names>DC</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name><name><surname>Visvanathan</surname><given-names>K</given-names></name><name><surname>Vodicka</surname><given-names>P</given-names></name><name><surname>Vodickova</surname><given-names>L</given-names></name><name><surname>Vymetalkova</surname><given-names>V</given-names></name><name><surname>Weigl</surname><given-names>K</given-names></name><name><surname>Weinstein</surname><given-names>SJ</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Woods</surname><given-names>MO</given-names></name><name><surname>Wu</surname><given-names>AH</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Gruber</surname><given-names>SB</given-names></name><name><surname>Hsu</surname><given-names>L</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genetic architectures of proximal and distal colorectal cancer are partly distinct</article-title><source>Gut</source><volume>70</volume><fpage>1325</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321534</pub-id><pub-id pub-id-type="pmid">33632709</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julkunen</surname><given-names>H</given-names></name><name><surname>Cichońska</surname><given-names>A</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Würtz</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population</article-title><source>eLife</source><volume>10</volume><elocation-id>e63033</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.63033</pub-id><pub-id pub-id-type="pmid">33942721</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Demissie</surname><given-names>S</given-names></name><name><surname>Musunuru</surname><given-names>K</given-names></name><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Kaplan</surname><given-names>L</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Crawford</surname><given-names>G</given-names></name><name><surname>Surti</surname><given-names>A</given-names></name><name><surname>Guiducci</surname><given-names>C</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>Parish</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Zelenika</surname><given-names>D</given-names></name><name><surname>Kubalanza</surname><given-names>KA</given-names></name><name><surname>Morken</surname><given-names>MA</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><name><surname>Galan</surname><given-names>P</given-names></name><name><surname>Swift</surname><given-names>AJ</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Sundvall</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Scheet</surname><given-names>P</given-names></name><name><surname>Sanna</surname><given-names>S</given-names></name><name><surname>Uda</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>de Bakker</surname><given-names>PIW</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Chambers</surname><given-names>JC</given-names></name><name><surname>Kooner</surname><given-names>JS</given-names></name><name><surname>Hercberg</surname><given-names>S</given-names></name><name><surname>Meneton</surname><given-names>P</given-names></name><name><surname>Lakatta</surname><given-names>EG</given-names></name><name><surname>Scuteri</surname><given-names>A</given-names></name><name><surname>Schlessinger</surname><given-names>D</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Lathrop</surname><given-names>GM</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name><name><surname>Orho-Melander</surname><given-names>M</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Common variants at 30 loci contribute to polygenic dyslipidemia</article-title><source>Nature Genetics</source><volume>41</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/ng.291</pub-id><pub-id pub-id-type="pmid">19060906</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khankari</surname><given-names>NK</given-names></name><name><surname>Banbury</surname><given-names>BL</given-names></name><name><surname>Borges</surname><given-names>MC</given-names></name><name><surname>Haycock</surname><given-names>P</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Arndt</surname><given-names>V</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Bézieau</surname><given-names>S</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Campbell</surname><given-names>PT</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Cotterchio</surname><given-names>M</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Figueiredo</surname><given-names>JC</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Jenkins</surname><given-names>MA</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Marchand</surname><given-names>LL</given-names></name><name><surname>Lemire</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>CI</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><name><surname>Martín</surname><given-names>V</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Pharoah</surname><given-names>PDP</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Sakoda</surname><given-names>LC</given-names></name><name><surname>Schafmayer</surname><given-names>C</given-names></name><name><surname>Schmit</surname><given-names>SL</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name><name><surname>Weinstein</surname><given-names>SJ</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Win</surname><given-names>AK</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Woods</surname><given-names>MO</given-names></name><name><surname>Wu</surname><given-names>AH</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Denny</surname><given-names>JC</given-names></name><name><surname>Edwards</surname><given-names>TL</given-names></name><name><surname>Murff</surname><given-names>HJ</given-names></name><name><surname>Gruber</surname><given-names>SB</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mendelian randomization of circulating polyunsaturated fatty acids and colorectal cancer risk</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>29</volume><fpage>860</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-0891</pub-id><pub-id pub-id-type="pmid">32051193</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauby-Secretan</surname><given-names>B</given-names></name><name><surname>Scoccianti</surname><given-names>C</given-names></name><name><surname>Loomis</surname><given-names>D</given-names></name><name><surname>Grosse</surname><given-names>Y</given-names></name><name><surname>Bianchini</surname><given-names>F</given-names></name><name><surname>Straif</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Body fatness and cancer--viewpoint of the IARC working group</article-title><source>The New England Journal of Medicine</source><volume>375</volume><fpage>794</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1056/NEJMsr1606602</pub-id><pub-id pub-id-type="pmid">27557308</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>PJ</given-names></name><name><surname>Timofeeva</surname><given-names>M</given-names></name><name><surname>Fernandez-Rozadilla</surname><given-names>C</given-names></name><name><surname>Broderick</surname><given-names>P</given-names></name><name><surname>Studd</surname><given-names>J</given-names></name><name><surname>Fernandez-Tajes</surname><given-names>J</given-names></name><name><surname>Farrington</surname><given-names>S</given-names></name><name><surname>Svinti</surname><given-names>V</given-names></name><name><surname>Palles</surname><given-names>C</given-names></name><name><surname>Orlando</surname><given-names>G</given-names></name><name><surname>Sud</surname><given-names>A</given-names></name><name><surname>Holroyd</surname><given-names>A</given-names></name><name><surname>Penegar</surname><given-names>S</given-names></name><name><surname>Theodoratou</surname><given-names>E</given-names></name><name><surname>Vaughan-Shaw</surname><given-names>P</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Zgaga</surname><given-names>L</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>S</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Starr</surname><given-names>J</given-names></name><name><surname>Gatcombe</surname><given-names>L</given-names></name><name><surname>Pinna</surname><given-names>M</given-names></name><name><surname>Briggs</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Jaeger</surname><given-names>E</given-names></name><name><surname>Sharma-Oates</surname><given-names>A</given-names></name><name><surname>East</surname><given-names>J</given-names></name><name><surname>Leedham</surname><given-names>S</given-names></name><name><surname>Arnold</surname><given-names>R</given-names></name><name><surname>Johnstone</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Kerr</surname><given-names>R</given-names></name><name><surname>Maughan</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Al-Tassan</surname><given-names>N</given-names></name><name><surname>Palin</surname><given-names>K</given-names></name><name><surname>Hänninen</surname><given-names>UA</given-names></name><name><surname>Cajuso</surname><given-names>T</given-names></name><name><surname>Tanskanen</surname><given-names>T</given-names></name><name><surname>Kondelin</surname><given-names>J</given-names></name><name><surname>Kaasinen</surname><given-names>E</given-names></name><name><surname>Sarin</surname><given-names>A-P</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><name><surname>Rissanen</surname><given-names>H</given-names></name><name><surname>Knekt</surname><given-names>P</given-names></name><name><surname>Pukkala</surname><given-names>E</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Renkonen-Sinisalo</surname><given-names>L</given-names></name><name><surname>Lepistö</surname><given-names>A</given-names></name><name><surname>Böhm</surname><given-names>J</given-names></name><name><surname>Mecklin</surname><given-names>J-P</given-names></name><name><surname>Buchanan</surname><given-names>DD</given-names></name><name><surname>Win</surname><given-names>A-K</given-names></name><name><surname>Hopper</surname><given-names>J</given-names></name><name><surname>Jenkins</surname><given-names>ME</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Duggan</surname><given-names>D</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Nöthen</surname><given-names>MM</given-names></name><name><surname>Jöckel</surname><given-names>K-H</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Pharoah</surname><given-names>PDP</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Swerdlow</surname><given-names>A</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Muir</surname><given-names>K</given-names></name><name><surname>Pashayan</surname><given-names>N</given-names></name><name><surname>Harkin</surname><given-names>A</given-names></name><name><surname>Allan</surname><given-names>K</given-names></name><name><surname>McQueen</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Saunders</surname><given-names>M</given-names></name><name><surname>Butterbach</surname><given-names>K</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Kirac</surname><given-names>I</given-names></name><name><surname>Matošević</surname><given-names>P</given-names></name><name><surname>Hofer</surname><given-names>P</given-names></name><name><surname>Brezina</surname><given-names>S</given-names></name><name><surname>Gsur</surname><given-names>A</given-names></name><name><surname>Cheadle</surname><given-names>JP</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Tomlinson</surname><given-names>I</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>Dunlop</surname><given-names>MG</given-names></name><collab>PRACTICAL consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Association analyses identify 31 new risk loci for colorectal cancer susceptibility</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2154</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09775-w</pub-id><pub-id pub-id-type="pmid">31089142</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leichtle</surname><given-names>AB</given-names></name><name><surname>Nuoffer</surname><given-names>JM</given-names></name><name><surname>Ceglarek</surname><given-names>U</given-names></name><name><surname>Kase</surname><given-names>J</given-names></name><name><surname>Conrad</surname><given-names>T</given-names></name><name><surname>Witzigmann</surname><given-names>H</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name><name><surname>Fiedler</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Serum amino acid profiles and their alterations in colorectal cancer</article-title><source>Metabolomics</source><volume>8</volume><fpage>643</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1007/s11306-011-0357-5</pub-id><pub-id pub-id-type="pmid">22833708</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>P</given-names></name><name><surname>Holm</surname><given-names>NV</given-names></name><name><surname>Verkasalo</surname><given-names>PK</given-names></name><name><surname>Iliadou</surname><given-names>A</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Koskenvuo</surname><given-names>M</given-names></name><name><surname>Pukkala</surname><given-names>E</given-names></name><name><surname>Skytthe</surname><given-names>A</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland</article-title><source>The New England Journal of Medicine</source><volume>343</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1056/NEJM200007133430201</pub-id><pub-id pub-id-type="pmid">10891514</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liyanage</surname><given-names>UE</given-names></name><name><surname>Ong</surname><given-names>JS</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Gharahkhani</surname><given-names>P</given-names></name><name><surname>Law</surname><given-names>MH</given-names></name><name><surname>MacGregor</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mendelian randomization study for genetically predicted polyunsaturated fatty acids levels on overall cancer risk and mortality</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>28</volume><fpage>1015</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-18-0940</pub-id><pub-id pub-id-type="pmid">30948449</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fatty acid synthase enhances colorectal cancer cell proliferation and metastasis via regulating AMPK/mTOR pathway</article-title><source>OncoTargets and Therapy</source><volume>12</volume><fpage>3339</fpage><lpage>3347</lpage><pub-id pub-id-type="doi">10.2147/OTT.S199369</pub-id><pub-id pub-id-type="pmid">31118685</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Tu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Blood lipids and risk of colon or rectal cancer: a Mendelian randomization study</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>147</volume><fpage>3591</fpage><lpage>3599</lpage><pub-id pub-id-type="doi">10.1007/s00432-021-03790-5</pub-id><pub-id pub-id-type="pmid">34490583</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer</article-title><source>Annals of Surgery</source><volume>255</volume><fpage>720</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e31824a9a8b</pub-id><pub-id pub-id-type="pmid">22395091</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamtani</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Scott</surname><given-names>FI</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Goldberg</surname><given-names>DS</given-names></name><name><surname>Datta</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>YX</given-names></name><name><surname>Boursi</surname><given-names>B</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disentangling the association between statins, cholesterol, and colorectal cancer: a nested case-control study</article-title><source>PLOS Medicine</source><volume>13</volume><elocation-id>e1002007</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1002007</pub-id><pub-id pub-id-type="pmid">27116322</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannes</surname><given-names>GA</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Thieme</surname><given-names>C</given-names></name><name><surname>Wiebecke</surname><given-names>B</given-names></name><name><surname>Paumgartner</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Relation between the frequency of colorectal adenoma and the serum cholesterol level</article-title><source>The New England Journal of Medicine</source><volume>315</volume><fpage>1634</fpage><lpage>1638</lpage><pub-id pub-id-type="doi">10.1056/NEJM198612253152602</pub-id><pub-id pub-id-type="pmid">3785334</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayengbam</surname><given-names>SS</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>AD</given-names></name><name><surname>Bhat</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Influence of cholesterol on cancer progression and therapy</article-title><source>Translational Oncology</source><volume>14</volume><elocation-id>101043</elocation-id><pub-id pub-id-type="doi">10.1016/j.tranon.2021.101043</pub-id><pub-id pub-id-type="pmid">33751965</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May Wilson</surname><given-names>S</given-names></name><name><surname>Sud</surname><given-names>A</given-names></name><name><surname>Law</surname><given-names>PJ</given-names></name><name><surname>Palin</surname><given-names>K</given-names></name><name><surname>Tuupanen</surname><given-names>S</given-names></name><name><surname>Gylfe</surname><given-names>A</given-names></name><name><surname>Hänninen</surname><given-names>UA</given-names></name><name><surname>Cajuso</surname><given-names>T</given-names></name><name><surname>Tanskanen</surname><given-names>T</given-names></name><name><surname>Kondelin</surname><given-names>J</given-names></name><name><surname>Kaasinen</surname><given-names>E</given-names></name><name><surname>Sarin</surname><given-names>AP</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><name><surname>Rissanen</surname><given-names>H</given-names></name><name><surname>Knekt</surname><given-names>P</given-names></name><name><surname>Pukkala</surname><given-names>E</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Renkonen-Sinisalo</surname><given-names>L</given-names></name><name><surname>Lepistö</surname><given-names>A</given-names></name><name><surname>Böhm</surname><given-names>J</given-names></name><name><surname>Mecklin</surname><given-names>JP</given-names></name><name><surname>Al-Tassan</surname><given-names>NA</given-names></name><name><surname>Palles</surname><given-names>C</given-names></name><name><surname>Farrington</surname><given-names>SM</given-names></name><name><surname>Timofeeva</surname><given-names>MN</given-names></name><name><surname>Meyer</surname><given-names>BF</given-names></name><name><surname>Wakil</surname><given-names>SM</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>CG</given-names></name><name><surname>Idziaszczyk</surname><given-names>S</given-names></name><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Kerr</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Passarelli</surname><given-names>MN</given-names></name><name><surname>Figueiredo</surname><given-names>JC</given-names></name><name><surname>Buchanan</surname><given-names>DD</given-names></name><name><surname>Win</surname><given-names>AK</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Jenkins</surname><given-names>MA</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Conti</surname><given-names>D</given-names></name><name><surname>Schumacher</surname><given-names>F</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Cheadle</surname><given-names>JP</given-names></name><name><surname>Tomlinson</surname><given-names>IP</given-names></name><name><surname>Dunlop</surname><given-names>MG</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis</article-title><source>European Journal of Cancer</source><volume>84</volume><fpage>228</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.07.034</pub-id><pub-id pub-id-type="pmid">28829991</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNabb</surname><given-names>S</given-names></name><name><surname>Harrison</surname><given-names>TA</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Caan</surname><given-names>BJ</given-names></name><name><surname>Campbell</surname><given-names>PT</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Hoffmeister</surname><given-names>M</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Männistö</surname><given-names>S</given-names></name><name><surname>Milne</surname><given-names>RL</given-names></name><name><surname>Nan</surname><given-names>H</given-names></name><name><surname>Newton</surname><given-names>CC</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Petersen</surname><given-names>PS</given-names></name><name><surname>Potter</surname><given-names>JD</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name><name><surname>Su</surname><given-names>YR</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Tucker</surname><given-names>TC</given-names></name><name><surname>Weinstein</surname><given-names>SJ</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><name><surname>Woods</surname><given-names>MO</given-names></name><name><surname>Phipps</surname><given-names>AI</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Meta-analysis of 16 studies of the association of alcohol with colorectal cancer</article-title><source>International Journal of Cancer</source><volume>146</volume><fpage>861</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1002/ijc.32377</pub-id><pub-id pub-id-type="pmid">31037736</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meester</surname><given-names>RGS</given-names></name><name><surname>van Herk</surname><given-names>M</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Ladabaum</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prevalence and clinical features of sessile serrated polyps: a systematic review</article-title><source>Gastroenterology</source><volume>159</volume><fpage>105</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.03.025</pub-id><pub-id pub-id-type="pmid">32199884</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiumi</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>A</given-names></name><name><surname>Yoshie</surname><given-names>T</given-names></name><name><surname>Kibi</surname><given-names>M</given-names></name><name><surname>Izumi</surname><given-names>Y</given-names></name><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Kawano</surname><given-names>S</given-names></name><name><surname>Takenawa</surname><given-names>T</given-names></name><name><surname>Azuma</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Creighton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel serum metabolomics-based diagnostic approach for colorectal cancer</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e40459</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0040459</pub-id><pub-id pub-id-type="pmid">22792336</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northstone</surname><given-names>K</given-names></name><name><surname>Lewcock</surname><given-names>M</given-names></name><name><surname>Groom</surname><given-names>A</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Macleod</surname><given-names>J</given-names></name><name><surname>Timpson</surname><given-names>N</given-names></name><name><surname>Wells</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019</article-title><source>Wellcome Open Research</source><volume>4</volume><elocation-id>51</elocation-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.15132.1</pub-id><pub-id pub-id-type="pmid">31020050</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocvirk</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>AS</given-names></name><name><surname>Appolonia</surname><given-names>CN</given-names></name><name><surname>Thomas</surname><given-names>TK</given-names></name><name><surname>O’Keefe</surname><given-names>SJD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fiber, fat, and colorectal cancer: new insight into modifiable dietary risk factors</article-title><source>Current Gastroenterology Reports</source><volume>21</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.1007/s11894-019-0725-2</pub-id><pub-id pub-id-type="pmid">31792624</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papandreou</surname><given-names>C</given-names></name><name><surname>García-Gavilán</surname><given-names>J</given-names></name><name><surname>Camacho-Barcia</surname><given-names>L</given-names></name><name><surname>Hansen</surname><given-names>TT</given-names></name><name><surname>Sjödin</surname><given-names>A</given-names></name><name><surname>Harrold</surname><given-names>JA</given-names></name><name><surname>Halford</surname><given-names>JCG</given-names></name><name><surname>Bulló</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Circulating metabolites associated with body fat and lean mass in adults with overweight/obesity</article-title><source>Metabolites</source><volume>11</volume><elocation-id>317</elocation-id><pub-id pub-id-type="doi">10.3390/metabo11050317</pub-id><pub-id pub-id-type="pmid">34068443</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Joo</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>YE</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Yoo</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Association of serum lipids and glucose with the risk of colorectal adenomatous polyp in men: a case-control study in Korea</article-title><source>Journal of Korean Medical Science</source><volume>15</volume><fpage>690</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.3346/jkms.2000.15.6.690</pub-id><pub-id pub-id-type="pmid">11194196</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>G</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>LX</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS</article-title><source>Journal of Proteome Research</source><volume>8</volume><fpage>4844</fpage><lpage>4850</lpage><pub-id pub-id-type="doi">10.1021/pr9004162</pub-id><pub-id pub-id-type="pmid">19678709</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rattner</surname><given-names>JI</given-names></name><name><surname>Kopciuk</surname><given-names>KA</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Tang</surname><given-names>PA</given-names></name><name><surname>Shapiro</surname><given-names>JD</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><name><surname>Jonker</surname><given-names>DJ</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>O’Callaghan</surname><given-names>CJ</given-names></name><name><surname>Bathe</surname><given-names>OF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Early detection of treatment futility in patients with metastatic colorectal cancer</article-title><source>Oncotarget</source><volume>13</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.28165</pub-id><pub-id pub-id-type="pmid">35028011</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rattray</surname><given-names>NJW</given-names></name><name><surname>Charkoftaki</surname><given-names>G</given-names></name><name><surname>Rattray</surname><given-names>Z</given-names></name><name><surname>Hansen</surname><given-names>JE</given-names></name><name><surname>Vasiliou</surname><given-names>V</given-names></name><name><surname>Johnson</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Environmental influences in the etiology of colorectal cancer: the premise of metabolomics</article-title><source>Current Pharmacology Reports</source><volume>3</volume><fpage>114</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1007/s40495-017-0088-z</pub-id><pub-id pub-id-type="pmid">28642837</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2021">2021</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>SA</given-names></name><name><surname>Ahiahonu</surname><given-names>PWK</given-names></name><name><surname>Jayasinghe</surname><given-names>D</given-names></name><name><surname>Heath</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Kavianpour</surname><given-names>A</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Khan</surname><given-names>AM</given-names></name><name><surname>Hossain</surname><given-names>M</given-names></name><name><surname>Su-Myat</surname><given-names>KK</given-names></name><name><surname>Wood</surname><given-names>PL</given-names></name><name><surname>Krenitsky</surname><given-names>K</given-names></name><name><surname>Takemasa</surname><given-names>I</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Sekimoto</surname><given-names>M</given-names></name><name><surname>Monden</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>F</given-names></name><name><surname>Goodenowe</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection</article-title><source>BMC Medicine</source><volume>8</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7015-8-13</pub-id><pub-id pub-id-type="pmid">20156336</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Broadbent</surname><given-names>H</given-names></name><name><surname>Law</surname><given-names>PJ</given-names></name><name><surname>Sud</surname><given-names>A</given-names></name><name><surname>Palin</surname><given-names>K</given-names></name><name><surname>Tuupanen</surname><given-names>S</given-names></name><name><surname>Gylfe</surname><given-names>A</given-names></name><name><surname>Hänninen</surname><given-names>UA</given-names></name><name><surname>Cajuso</surname><given-names>T</given-names></name><name><surname>Tanskanen</surname><given-names>T</given-names></name><name><surname>Kondelin</surname><given-names>J</given-names></name><name><surname>Kaasinen</surname><given-names>E</given-names></name><name><surname>Sarin</surname><given-names>AP</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><name><surname>Rissanen</surname><given-names>H</given-names></name><name><surname>Knekt</surname><given-names>P</given-names></name><name><surname>Pukkala</surname><given-names>E</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Renkonen-Sinisalo</surname><given-names>L</given-names></name><name><surname>Lepistö</surname><given-names>A</given-names></name><name><surname>Böhm</surname><given-names>J</given-names></name><name><surname>Mecklin</surname><given-names>JP</given-names></name><name><surname>Al-Tassan</surname><given-names>NA</given-names></name><name><surname>Palles</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Barclay</surname><given-names>E</given-names></name><name><surname>Farrington</surname><given-names>SM</given-names></name><name><surname>Timofeeva</surname><given-names>MN</given-names></name><name><surname>Meyer</surname><given-names>BF</given-names></name><name><surname>Wakil</surname><given-names>SM</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>CG</given-names></name><name><surname>Idziaszczyk</surname><given-names>S</given-names></name><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Passarelli</surname><given-names>MN</given-names></name><name><surname>Figueiredo</surname><given-names>JC</given-names></name><name><surname>Buchanan</surname><given-names>DD</given-names></name><name><surname>Win</surname><given-names>AK</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Jenkins</surname><given-names>MA</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Conti</surname><given-names>D</given-names></name><name><surname>Schumacher</surname><given-names>F</given-names></name><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Cheadle</surname><given-names>JP</given-names></name><name><surname>Tomlinson</surname><given-names>IP</given-names></name><name><surname>Dunlop</surname><given-names>MG</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer</article-title><source>International Journal of Cancer</source><volume>140</volume><fpage>2701</fpage><lpage>2708</lpage><pub-id pub-id-type="doi">10.1002/ijc.30709</pub-id><pub-id pub-id-type="pmid">28340513</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Scheinin</surname><given-names>I</given-names></name><name><surname>Kalimeri</surname><given-names>M</given-names></name><name><surname>Jagerroos</surname><given-names>V</given-names></name><name><surname>Parkkinen</surname><given-names>J</given-names></name><name><surname>Tikkanen</surname><given-names>E</given-names></name><name><surname>Würtz</surname><given-names>P</given-names></name><name><surname>Kangas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Ggforestplot: Forestplots of measures of effects and their confidence intervals</data-title><version designator="0.1.0">0.1.0</version><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://nightingalehealth.github.io/ggforestplot/index.html">https://nightingalehealth.github.io/ggforestplot/index.html</ext-link></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singla</surname><given-names>P</given-names></name><name><surname>Bardoloi</surname><given-names>A</given-names></name><name><surname>Parkash</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Metabolic effects of obesity: A review</article-title><source>World Journal of Diabetes</source><volume>1</volume><fpage>76</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.4239/wjd.v1.i3.76</pub-id><pub-id pub-id-type="pmid">21537431</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>“Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title><source>International Journal of Epidemiology</source><volume>32</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/ije/dyg070</pub-id><pub-id pub-id-type="pmid">12689998</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudlow</surname><given-names>C</given-names></name><name><surname>Gallacher</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>N</given-names></name><name><surname>Beral</surname><given-names>V</given-names></name><name><surname>Burton</surname><given-names>P</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Downey</surname><given-names>P</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Landray</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Matthews</surname><given-names>P</given-names></name><name><surname>Ong</surname><given-names>G</given-names></name><name><surname>Pell</surname><given-names>J</given-names></name><name><surname>Silman</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Sprosen</surname><given-names>T</given-names></name><name><surname>Peakman</surname><given-names>T</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title><source>PLOS Medicine</source><volume>12</volume><elocation-id>e1001779</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001779</pub-id><pub-id pub-id-type="pmid">25826379</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Kisialiou</surname><given-names>A</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Bandinelli</surname><given-names>S</given-names></name><name><surname>Cherubini</surname><given-names>A</given-names></name><name><surname>Arnett</surname><given-names>D</given-names></name><name><surname>Tsai</surname><given-names>MY</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study</article-title><source>PLOS Genetics</source><volume>5</volume><elocation-id>e1000338</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000338</pub-id><pub-id pub-id-type="pmid">19148276</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>FY</given-names></name><name><surname>Pai</surname><given-names>MH</given-names></name><name><surname>Chiang</surname><given-names>EPI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model</article-title><source>The Journal of Nutritional Biochemistry</source><volume>23</volume><fpage>1302</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2011.07.011</pub-id><pub-id pub-id-type="pmid">22221675</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The association between serum lipids and colorectal neoplasm: a systemic review and meta-analysis</article-title><source>Public Health Nutrition</source><volume>18</volume><fpage>3355</fpage><lpage>3370</lpage><pub-id pub-id-type="doi">10.1017/S1368980015000646</pub-id><pub-id pub-id-type="pmid">25776573</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>MJ</given-names></name><name><surname>Allen</surname><given-names>B</given-names></name><name><surname>Palacios</surname><given-names>OM</given-names></name><name><surname>Haber</surname><given-names>LT</given-names></name><name><surname>Maki</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol</article-title><source>The American Journal of Clinical Nutrition</source><volume>109</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqy273</pub-id><pub-id pub-id-type="pmid">30596814</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Metabolic reprogramming: a cancer hallmark even warburg did not anticipate</article-title><source>Cancer Cell</source><volume>21</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.02.014</pub-id><pub-id pub-id-type="pmid">22439925</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Würtz</surname><given-names>P</given-names></name><name><surname>Kangas</surname><given-names>AJ</given-names></name><name><surname>Soininen</surname><given-names>P</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Ala-Korpela</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: A Primer on -Omic Technologies</article-title><source>American Journal of Epidemiology</source><volume>186</volume><fpage>1084</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1093/aje/kwx016</pub-id><pub-id pub-id-type="pmid">29106475</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Rao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis</article-title><source>BMJ Open</source><volume>12</volume><elocation-id>e052373</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2021-052373</pub-id><pub-id pub-id-type="pmid">35732386</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies</article-title><source>Cancer Causes &amp; Control</source><volume>26</volume><fpage>257</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1007/s10552-014-0507-y</pub-id><pub-id pub-id-type="pmid">25488827</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarmolinsky</surname><given-names>J</given-names></name><name><surname>Wade</surname><given-names>KH</given-names></name><name><surname>Richmond</surname><given-names>RC</given-names></name><name><surname>Langdon</surname><given-names>RJ</given-names></name><name><surname>Bull</surname><given-names>CJ</given-names></name><name><surname>Tilling</surname><given-names>KM</given-names></name><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Lewis</surname><given-names>SJ</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Causal inference in cancer epidemiology: what is the role of mendelian randomization?</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>27</volume><fpage>995</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-17-1177</pub-id><pub-id pub-id-type="pmid">29941659</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaytseva</surname><given-names>YY</given-names></name><name><surname>Rychahou</surname><given-names>PG</given-names></name><name><surname>Le</surname><given-names>AT</given-names></name><name><surname>Scott</surname><given-names>TL</given-names></name><name><surname>Flight</surname><given-names>RM</given-names></name><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>AJ</given-names></name><name><surname>Sivakumaran</surname><given-names>TA</given-names></name><name><surname>Fan</surname><given-names>T</given-names></name><name><surname>Moseley</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Weiss</surname><given-names>HL</given-names></name><name><surname>Heuer</surname><given-names>TS</given-names></name><name><surname>Kemble</surname><given-names>G</given-names></name><name><surname>Evers</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer</article-title><source>Oncotarget</source><volume>9</volume><fpage>24787</fpage><lpage>24800</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25361</pub-id><pub-id pub-id-type="pmid">29872506</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Metabolomics in diagnosis and biomarker discovery of colorectal cancer</article-title><source>Cancer Letters</source><volume>345</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.11.011</pub-id><pub-id pub-id-type="pmid">24333717</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Study funding</title><sec sec-type="appendix" id="s8-1"><title>ALSPAC</title><p>The UK Medical Research Council and Wellcome (grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors who will serve as guarantors for the<ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf">on the ALSPAC website</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf">on the ALSPAC website</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf">on the ALSPAC website</ext-link> contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (<ext-link ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf">http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf</ext-link>); this research was specifically funded by the UK Medical Research Council (grant ref: MC_UU_12013/1). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.</p></sec><sec sec-type="appendix" id="s8-2"><title>Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)</title><p>National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01 CA137088, R01 CA059045, R01 201407). Genotyping/Sequencing services were provided by the Center for Inherited Disease Research (CIDR) contract number HHSN268201700006I and HHSN268201200008I. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685.</p></sec><sec sec-type="appendix" id="s8-3"><title>ASTERISK</title><p>A Hospital Clinical Research Program (PHRC-BRD09/C) from the University Hospital Center of Nantes (CHU de Nantes) and supported by the Regional Council of Pays de la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Génétique, and the Ligue Régionale Contre le Cancer (LRCC).</p><p>The ATBC Study is supported by the Intramural Research Program of the U.S. National Cancer Institute, National Institutes of Health, Department of Health and Human Services.</p><p>CLUE II funding was from the National Cancer Institute (U01 CA086308, Early Detection Research Network; P30 CA006973), National Institute on Aging (U01 AG018033), and the American Institute for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.</p></sec><sec sec-type="appendix" id="s8-4"><title>Maryland Cancer Registry (MCR)</title><p>Cancer data was provided by the Maryland Cancer Registry, Center for Cancer Prevention and Control, Maryland Department of Health, with funding from the State of Maryland and the Maryland Cigarette Restitution Fund. The collection and availability of cancer registry data are also supported by the Cooperative Agreement NU58DP006333, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.</p></sec><sec sec-type="appendix" id="s8-5"><title>ColoCare</title><p>This work was supported by the National Institutes of Health (grant numbers R01 CA189184 [Li/Ulrich], U01 CA206110 [Ulrich/Li/Siegel/Figueiredo/Colditz, 2P30CA015704-40; Gilliland, R01 CA207371 Ulrich/Li]), the Matthias Lackas-Foundation, the German Consortium for Translational Cancer Research, and the EU TRANSCAN initiative.</p><p>The Colon Cancer Family Registry (CCFR, <ext-link ext-link-type="uri" xlink:href="https://www.coloncfr.org/">https://www.coloncfr.org/</ext-link>) is supported in part by funding from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551). Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and End Results (SEER) Program and the following US state cancer registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada). The CCFR Set-1 (Illumina 1M/1M-Duo) and Set-2 (Illumina Omni1-Quad) scans were supported by NIH awards U01 CA122839 and R01 CA143237 (to GC). The CCFR Set-3 (Affymetrix Axiom CORECT Set array) was supported by NIH award U19 CA148107 and R01 CA81488 (to SBG). The CCFR Set-4 (Illumina OncoArray 600K SNP array) was supported by NIH award U19 CA148107 (to SBG) and by the Center for Inherited Disease Research (CIDR), which is funded by the NIH to the Johns Hopkins University, contract number HHSN268201200008I. Additional funding for the OFCCR/ARCTIC was through award GL201-043 from the Ontario Research Fund (to BWZ), award 112746 from the Canadian Institutes of Health Research (to TJH), through a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society (to SG), and through generous support from the Ontario Ministry of Research and Innovation. The SFCCR Illumina HumanCytoSNP array was supported in part through NCI/NIH awards U01/U24 CA074794 and R01 CA076366 (to PAN). The content of this manuscript does not necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centres in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government, any cancer registry, or the CCFR.</p></sec><sec sec-type="appendix" id="s8-6"><title>COLON</title><p>The COLON study is sponsored by Wereld Kanker Onderzoek Fonds, including funds from grant 2014/1179 as part of the World Cancer Research Fund International Regular Grant Programme, by Alpe d’Huzes and the Dutch Cancer Society (UM 2012-5653, UW 2013-5927, UW2015-7946), and by TRANSCAN (JTC2012-MetaboCCC, JTC2013-FOCUS). The Nqplus study is sponsored by a ZonMW investment grant (98-10030); by PREVIEW, the project PREVention of diabetes through lifestyle intervention and population studies in Europe and around the World (PREVIEW) project which received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant no. 312057; by funds from TI Food and Nutrition (cardiovascular health theme), a public–private partnership on precompetitive research in food and nutrition; and by FOODBALL, the Food Biomarker Alliance, a project from JPI Healthy Diet for a Healthy Life.</p></sec><sec sec-type="appendix" id="s8-7"><title>COLO2&amp;3</title><p>National Institutes of Health (R01 CA060987).</p></sec><sec sec-type="appendix" id="s8-8"><title>Colorectal Cancer Transdisciplinary (CORECT) study</title><p>The CORECT study was supported by the National Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of Health and Human Services (grant numbers U19 CA148107, R01 CA081488, P30 CA014089, R01 CA197350; P01 CA196569; R01 CA201407; R01 CA242218), National Institutes of Environmental Health Sciences, National Institutes of Health (grant number T32 ES013678), and a generous gift from Daniel and Maryann Fong.</p></sec><sec sec-type="appendix" id="s8-9"><title>CORSA</title><p>The CORSA study was funded by the Austrian Research Funding Agency (FFG) BRIDGE (grant 829675, to Andrea Gsur), the ‘Herzfelder’sche Familienstiftung’ (grant to Andrea Gsur) and was supported by COST Action BM1206.</p></sec><sec sec-type="appendix" id="s8-10"><title>CPS-II</title><p>The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. The study protocol was approved by the institutional review boards of Emory University, and those of participating registries as required.</p></sec><sec sec-type="appendix" id="s8-11"><title>CRCGEN</title><p>The Colorectal Cancer Genetics &amp; Genomics, Spanish study was supported by Instituto de Salud Carlos III, co-funded by FEDER funds – a way to build Europe (grants PI14-613 and PI09-1286), Agency for Management of University and Research Grants (AGAUR) of the Catalan Government (grant 2017SGR723), Junta de Castilla y León (grant LE22A10-2), the Spanish Association Against Cancer (AECC) Scientific Foundation grant GCTRA18022MORE, and the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), action Genrisk. Sample collection of this work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncología de Catalunya (XBTC), Plataforma Biobancos PT13/0010/0013, and ICOBIOBANC, sponsored by the Catalan Institute of Oncology. We thank CERCA Programme, Generalitat de Catalunya, for institutional support.</p></sec><sec sec-type="appendix" id="s8-12"><title>Czech Republic CCS</title><p>This work was supported by the Grant Agency of the Czech Republic (21-04607X, 20-03997S), the Grant Agency of the Ministry of Health of the Czech Republic (grants AZV NU21-07-00247 and AZV NU21-03-00506), and Charles University Research Fund (Cooperation 43-Surgical disciplines)</p></sec><sec sec-type="appendix" id="s8-13"><title>DACHS</title><p>This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, and BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, and 01ER1505B).</p></sec><sec sec-type="appendix" id="s8-14"><title>DALS</title><p>National Institutes of Health (R01 CA048998 to ML Slattery).</p></sec><sec sec-type="appendix" id="s8-15"><title>EDRN</title><p>This work is funded and supported by the NCI, EDRN Grant (U01-CA152753).</p></sec><sec sec-type="appendix" id="s8-16"><title>EPIC</title><p>The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam- Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) – Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology – ICO (Spain); Swedish Cancer Society, Swedish Research Council and Region Skåne and Region Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (the United Kingdom).</p></sec><sec sec-type="appendix" id="s8-17"><title>EPICOLON</title><p>This work was supported by grants from Fondo de Investigación Sanitaria/FEDER (PI08/0024, PI08/1276, PS09/02368, PI11/00219, PI11/00681, PI14/00173, PI14/00230, PI17/00509, 17/00878, PI20/00113, PI20/00226, Acción Transversal de Cáncer), Xunta de Galicia (PGIDIT07PXIB9101209PR), Ministerio de Economia y Competitividad (SAF07-64873, SAF 2010-19273, SAF2014-54453R), Fundación Científica de la Asociación Española contra el Cáncer (GCB13131592CAST, PRYGN211085CAST), Beca Grupo de Trabajo ‘Oncología’ AEG (Asociación Española de Gastroenterología), Fundación Privada Olga Torres, FP7 CHIBCHA Consortium, Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya, 2014SGR135, 2014SGR255, 2017SGR21, 2017SGR653, 2021SGR00716, 2021SGR01185), Catalan Tumour Bank Network (Pla Director d’Oncologia, Generalitat de Catalunya), PERIS (SLT002/16/00398, Generalitat de Catalunya), Marató TV3 (202008-10), CERCA Programme (Generalitat de Catalunya), and COST Actions BM1206 and CA17118. CIBERehd is funded by the Instituto de Salud Carlos III.ESTHER/VERDI. This work was supported by grants from the Baden-Württemberg Ministry of Science, Research and Arts, and the German Cancer Aid.</p></sec><sec sec-type="appendix" id="s8-18"><title>Harvard cohorts</title><p>HPFS is supported by the National Institutes of Health (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, and R35 CA197735), NHS by the National Institutes of Health (P01 CA087969, UM1 CA186107, R01 CA137178, R01 CA151993, and R35 CA197735), and PHS by the National Institutes of Health (R01 CA042182).</p></sec><sec sec-type="appendix" id="s8-19"><title>Hawaii Adenoma Study</title><p>NCI grants R01 CA072520.</p></sec><sec sec-type="appendix" id="s8-20"><title>HCES-CRC</title><p>The Hwasun Cancer Epidemiology Study – Colon and Rectum Cancer (HCES-CRC; grants from Chonnam National University Hwasun Hospital, HCRI15011-1).</p></sec><sec sec-type="appendix" id="s8-21"><title>Kentucky</title><p>This work was supported by the following grant support: Clinical Investigator Award from Damon Runyon Cancer Research Foundation (CI-8); NCI R01CA136726.</p></sec><sec sec-type="appendix" id="s8-22"><title>LCCS</title><p>The Leeds Colorectal Cancer Study was funded by the Food Standards Agency and Cancer Research UK Programme Award (C588/A19167).</p><p>MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 509348, 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. BMLynch was supported by MCRF18005 from the Victorian Cancer Agency.</p></sec><sec sec-type="appendix" id="s8-23"><title>MEC</title><p>National Institutes of Health (R37 CA054281, P01 CA033619, and R01 CA063464).</p></sec><sec sec-type="appendix" id="s8-24"><title>MECC</title><p>This work was supported by the National Institutes of Health, U.S. Department of Health and Human Services R01 CA081488, R01 CA197350, U19 CA148107, R01 CA242218, and a generous gift from Daniel and Maryann Fong.</p></sec><sec sec-type="appendix" id="s8-25"><title>MSKCC</title><p>The work at Sloan Kettering in New York was supported by the Robert and Kate Niehaus Center for Inherited Cancer Genomics and the Romeo Milio Foundation. Moffitt: This work was supported by funding from the National Institutes of Health (grant numbers R01 CA189184, P30 CA076292), Florida Department of Health Bankhead-Coley Grant 09BN-13, and the University of South Florida Oehler Foundation. Moffitt contributions were supported in part by the Total Cancer Care Initiative, Collaborative Data Services Core, and Tissue Core at the H. Lee Moffitt Cancer Center &amp; Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center (grant number P30 CA076292).</p></sec><sec sec-type="appendix" id="s8-26"><title>NCCCS I and II</title><p>We acknowledge funding support for this project from the National Institutes of Health, R01 CA066635 and P30 DK034987.</p></sec><sec sec-type="appendix" id="s8-27"><title>NFCCR</title><p>This work was supported by an Interdisciplinary Health Research Team award from the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health, U.S. Department of Health and Human Services (U01 CA074783); and National Cancer Institute of Canada grants (18223 and 18226). The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team of the McGill University and Génome Québec Innovation Centre, Montréal, Canada, for genotyping the Sequenom panel in the NFCCR samples. Funding was provided to Michael O. Woods by the Canadian Cancer Society Research Institute.</p></sec><sec sec-type="appendix" id="s8-28"><title>NSHDS</title><p>The research was supported by Biobank Sweden through funding from the Swedish Research Council (VR 2017-00650, VR 2017-01737), the Swedish Cancer Society (CAN 2017/581), Region Västerbotten (VLL-841671, VLL-833291), Knut and Alice Wallenberg Foundation (VLL-765961), and the Lion’s Cancer Research Foundation (several grants) and Insamlingsstiftelsen, both at Umeå University.</p></sec><sec sec-type="appendix" id="s8-29"><title>OSUMC</title><p>OCCPI funding was provided by Pelotonia and HNPCC funding was provided by the NCI (CA016058 and CA067941).</p></sec><sec sec-type="appendix" id="s8-30"><title>PLCO</title><p>Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. Funding was provided by National Institutes of Health (NIH), Genes, Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI U01 HG 004438.</p></sec><sec sec-type="appendix" id="s8-31"><title>SEARCH</title><p>The University of Cambridge has received salary support in respect of PDPP from the NHS in the East of England through the Clinical Academic Reserve. Cancer Research UK (C490/A16561); the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge.</p></sec><sec sec-type="appendix" id="s8-32"><title>SELECT</title><p>Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under Award Numbers U10 CA037429 (CD Blanke), and UM1 CA182883 (CM Tangen/IM Thompson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></sec><sec sec-type="appendix" id="s8-33"><title>SMS and REACHS</title><p>This work was supported by the National Cancer Institute (grant P01 CA074184 to JDP and PAN, grants R01 CA097325, R03 CA153323, and K05 CA152715 to PAN), and the National Center for Advancing Translational Sciences at the National Institutes of Health (grant KL2 TR000421 to ANB-H).</p></sec><sec sec-type="appendix" id="s8-34"><title>The Swedish Low-Risk Colorectal Cancer Study</title><p>The study was supported by grants from the Swedish research council; K2015-55X-22674-01-4, K2008-55X-20157-03-3, K2006-72X-20157-01-2, and the Stockholm County Council (ALF project).</p></sec><sec sec-type="appendix" id="s8-35"><title>Swedish Mammography Cohort and Cohort of Swedish Men</title><p>This work is supported by the Swedish Research Council /Infrastructure grant, the Swedish Cancer Foundation, and the Karolinska Institute’s Distinguished Professor Award to Alicja Wolk.</p></sec><sec sec-type="appendix" id="s8-36"><title>UK Biobank</title><p>This research has been conducted using the UK Biobank Resource under Application Number 8614</p></sec><sec sec-type="appendix" id="s8-37"><title>VITAL</title><p>National Institutes of Health (K05 CA154337).</p><p>The WHI programme is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, and 75N92021D00005.</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87894.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hägg</surname><given-names>Sara</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Karolinska Institutet</institution><country>Sweden</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>The by Bull et al. provides <bold>valuable</bold> information on the relationship between metabolic features, in particular different lipoproteins and fatty acids, and colorectal cancer. They use <bold>solid</bold> methods and combine different data sources to analyze forward and reverse Mendelian randomizations that support their claims.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87894.3.sa1</article-id><title-group><article-title>Joint Public Review:</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Bull et al aimed to use data from observational studies and mendelian randomisation to explore if changes in circulating metabolites are associated with colorectal cancer development. As Mendelian randomisation uses information on genetic variations which are fixed at birth, it is less vulnerable to confounding than standard observational studies.</p><p>Overall, a major strength of the study is that it uses data from large cohort studies, one from childhood, adolescence, and early adulthood when the incidence of colorectal cancer is very low (reducing the likelihood of reverse causation) and before medication (such as statins which have the potential to affect metabolite levels) has been initiated.</p><p>This study has some weaknesses which have been acknowledged by the authors. Although the findings of this study indicate the potentially significant role that polyunsaturated fatty acids may have in colorectal cancer risk, the genes and therefore also the genetic variations (SNPs) associated with fatty acids often produce an effect for more than one fatty acid which may introduce bias. This together with the fact that there was limited information available on many specific fatty acids which are known causative metabolites for colorectal cancer, makes it difficult to establish with confidence which specific classes of fatty acids could potentially play a causative role in these associations. Also, the study populations are majority white European descent which may limit the generalizability of these findings to other populations.</p><p>The methodology used was largely acceptable to achieve the aims set out and the findings have shown an association between polyunsaturated fat levels and genetic liability to colorectal cancer.</p><p>Overall, this is an important piece of work which has the potential to contribute to our understanding of the causal relationship between circulating metabolites at different stages of the life cycle and colorectal cancer risk as it would be extremely difficult to gather such evidence using other study designs. It opens the door for future research aiming to better understand the role that these metabolites could play in colorectal cancer risk prediction and in turn help identify groups of individuals who would benefit most from prevention and early detection interventions.</p><p>This work will be of interest not only to epidemiologists working in the area of GI tract cancers but also those interested in the different applications for mendelian randomisation within cancer epidemiology research.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87894.3.sa2</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bull</surname><given-names>Caroline</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Hazelwood</surname><given-names>Emma</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bell</surname><given-names>Joshua A</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Vanessa</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Constantinescu</surname><given-names>Andrei-Emil</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Borges</surname><given-names>Carolina</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Legge</surname><given-names>Danny</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Burrows</surname><given-names>Kimberley</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Huyghe</surname><given-names>Jeroen R</given-names></name><role specific-use="author">Author</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><addr-line><named-content content-type="city">Seattle, Washington</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>Hermann</given-names></name><role specific-use="author">Author</role><aff><institution>German Cancer Research Center</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Castellvi-Bel</surname><given-names>Sergi</given-names></name><role specific-use="author">Author</role><aff><institution>Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Andrew T</given-names></name><role specific-use="author">Author</role><aff><institution>Harvard University</institution><addr-line><named-content content-type="city">Boston, Massachusetts</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kweon</surname><given-names>Sun-Seog</given-names></name><role specific-use="author">Author</role><aff><institution>Chonnam National University Hwasun Hospital</institution><addr-line><named-content content-type="city">Gwangju</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Le Marchand</surname><given-names>Loic</given-names></name><role specific-use="author">Author</role><aff><institution>University of Hawaii at Manoa</institution><addr-line><named-content content-type="city">Honolulu</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Li</given-names></name><role specific-use="author">Author</role><aff><institution>University of Virginia</institution><addr-line><named-content content-type="city">Charlottesville, Virginia</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Iona</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">Fremont</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Pai</surname><given-names>Rish K</given-names></name><role specific-use="author">Author</role><aff><institution>Mayo Clinic</institution><addr-line><named-content content-type="city">Scottsdale, Arizona</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Figueiredo</surname><given-names>Jane C</given-names></name><role specific-use="author">Author</role><aff><institution>University of Southern California</institution><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>Neil</given-names></name><role specific-use="author">Author</role><aff><institution>International Agency For Research On Cancer</institution><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Gunter</surname><given-names>Marc J</given-names></name><role specific-use="author">Author</role><aff><institution>Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Timpson</surname><given-names>Nicholas J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Vincent</surname><given-names>Emma E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><p>We would like to thank the reviewers for their helpful comments which we have addressed, point-by-point, below:</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1:</bold></p><p>1. It might be useful to add more details to the methods (especially lines 191-196) to make them a bit more user-friendly for an audience who still may be unfamiliar with the relatively new and complex Mendelian randomisation technique.</p></disp-quote><p>The following information has been included in this section of the methods, to describe the different MR models in more detail:</p><p>“The IVW MR model will produce biased effect estimates in the presence of horizontal pleiotropy, i.e. where one or more genetic variant(s) included in the instrument affect the outcome by a pathway other than through the exposure. In the weighted median model, each genetic variant is weighted according to its distance from the median effect of all genetic variants. Thus, the weighted median model will provide an unbiased estimate when at least 50% of the information in an instrument comes from genetic variants that are not horizontally pleiotropic. The weighted mode model uses a similar approach but weights genetic instruments according to the mean effect. In this model, over 50% of the weight of the genetic instrument can be contributed to by genetic variants which are horizontally pleiotropic, but the most common amount of pleiotropy must be zero (known as the Zero Modal Pleiotropy Assumption (ZEMPA))[Hartwig et al., 2017].”</p><disp-quote content-type="editor-comment"><p>2. I was just wondering why MR egger was not carried out as part of this analysis?</p></disp-quote><p>We did consider also employing the MR Egger model as a further sensitivity analysis. However, given we were already employing the weighted median and weighted mode models, and given that MR-Egger suffers from reduced statistical power in comparison to the other models, we reasoned that adding in a further MR model would not add further clarity to our analyses, particularly given the relatively small sample size.</p><disp-quote content-type="editor-comment"><p>3. Although it is included in Figure 1 flowchart, I think it is also important to explain clearly in the written text way only n=6,118 of n=13,988 children in ALSPAC study were included in this study and the reason for this.</p></disp-quote><p>The following information has been included in the paragraph describing the ALSPAC study in the methods:</p><p>“Sufficient information was available on 6,221 of these individuals to be included in our analysis, as metabolomics was not performed for all individuals in the ALSPAC study.”</p><disp-quote content-type="editor-comment"><p>4. It is mentioned within the discussion 'the NMR metabolomics platform utilised in the analyses outlined here has limited coverage of fatty acids'. I think it might be useful to also add this detail into the methods section to aid readers when they are making their own interpretation whilst reading the results section.</p></disp-quote><p>The following sentence has been included in the methods section:</p><p>“This metabolomics platform has limited coverage of fatty acids.”</p><disp-quote content-type="editor-comment"><p>5. However, I feel that the conclusion should be tempered slightly as although this study alongside other similar MR studies provides evidence of an association between genetic liability to CRC and levels of metabolites at certain ages, I do not think there is enough evidence at this stage to say that genetic liability for CRC actually alters the levels of metabolites.</p></disp-quote><p>The first sentence of the conclusion has been changed to:</p><p>“Our analysis provides evidence that genetic liability to CRC is associated with altered levels of metabolites at certain ages, some of which may have a causal role in CRC development.”</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2:</bold></p><p>1. The background is lacking introduction to the different components of the metabolic features tested. For instance, there is a broader discussion about polyunsaturated fatty acids (PUFA) in the discussion, however, this should have been introduced and defined already before that. What metabolites are included in that term (PUFA)? Are there other studies on PUFA and CRC?</p></disp-quote><p>The following information has been included in the background section:</p><p>“In particular, previous work has highlighted polyunsaturated fatty acids (PUFA) as potentially having a role in colorectal cancer development. The term PUFA includes omega-3 and -6 fatty acids. Recent MR work has highlighted a possible link between PUFAs, in particular omega 6 PUFAs, and colorectal cancer risk.”</p><disp-quote content-type="editor-comment"><p>2. There seem to be indications for horizontal pleiotropy given the changed estimates when genetic variants in the FADS loci are removed. Could multivariable MR methods have been used to account for pleiotropy and differentiate individual fatty acid effects?</p></disp-quote><p>Multivariable MR can be employed to investigate the effects of horizontal pleiotropy. However, the multiple exposures must have sufficiently distinct underlying genetic architecture in order to instrument each one whilst adjusting for the other, as determined by conditional F-statistics. Given the correlations across metabolite levels, this is unlikely to be the case.</p><disp-quote content-type="editor-comment"><p>3. The ALSPAC sample sizes are decreasing across the different age groups, which is not strange given the longitudinal collection. However, does the altered sample composition affect the results? Have sensitivity analyses been done on the complete set of individuals from age 8-25?</p></disp-quote><p>The altered sample composition could be affecting results. The limitations section of the discussion has been amended to reflect this:</p><p>“Secondly, mostly due to the longitudinal nature of the ASLAPC study, our sample at each time point is composed of slightly different individuals. This could be influencing our results, and should be taken into account when comparing across time points.”</p><p>We have not completed any sensitivity analyses to investigate this.</p><disp-quote content-type="editor-comment"><p>4. Although beyond the scope of this paper, sex-stratified GWAS analyses on metabolites can easily be done in UK Biobank.</p></disp-quote><p>We thank the reviewer for this suggestion, and agree that this would be an interesting future analysis. We have amended the discussion to mention this:</p><p>“Fourthly, our analysis would benefit from being repeated with sex-stratified data. Although such GWAS results for metabolites are not currently available, the data to perform such GWAS are available in UK Biobank for future analyses.”</p><disp-quote content-type="editor-comment"><p>5. Very minor, there is a difference in reporting a number of decimals in ALSPAC results.There is also a difference in reporting the units for the results comparing text and figures (per SD higher CRC liability or per doubling). Please include sample sizes and data sources in the figure legends as they should be stand-alone items.</p></disp-quote><p>We have amended the ALSPAC results to all have two decimal places, reporting units have been altered and figure legends to include sample sizes and data sources.</p></body></sub-article></article>